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Summary 
FK506 binding protein 5 (FKBP5) has been linked to stress related diseases and 
treatment response in depression (Binder et al., 2004). The corresponding protein 
FKBP51 was first identified as co-chaperone of HSP90 in a complex with steroid 
hormone receptors, where it diminishes hormone affinity and nuclear translocation 
efficiency of the receptors (Pratt and Toft, 1997; Wochnik et al., 2005). With FKBP5 
transcription being induced by glucocorticoid signalling, an ultra-short feedback loop is 
provided for regulation and termination of GR activity. Dysregulation of this ultra-short 
feedback loop interferes with the stress hormone regulation and likely contributes to the 
association of FKBP5 with stress-related psychiatric disorders. Recently, important 
actions of FKBP51 beyond glucocorticoid signalling have been characterised in shaping 
the posttranslational regulation of certain molecular pathways in response to treatment 
with particular psychopharmaca (Gassen et al., 2014, 2015). 
As a contribution to elucidating the role of FKBP5 in stress related diseases, a two-sided 
approach was taken in this study by analysing the role of FKBP5 in regulation of 
transcription and in calibrating the responsiveness of these pathways to 
psychopharmacological treatment. 
To elucidate the transcriptional effects of FKBP5 in an unbiased approach, the expression 
profile of mice with deleted FKBP5 and their litter mates with functional FKBP5 were 
compared. A marked difference in glyoxalase-1 (GLO1) transcription was observed with 
higher GLO1 transcription in mice with deleted FKBP5, which was reflected by about 
two-fold more GLO1 protein in these mice. The efforts in deciphering the role of FKBP5 
in elevation of GLO1 expression led to the identification of a duplication of the GLO1 
gene inherent to mice with deleted FKBP5; this likely explains the enhanced GLO1 
expression in these mice. This observation exemplifies the flanking gene problem and is 
a note of caution for interpreting data from conventionally generated knock-out mice. 
Overall, deletion of FKBP5 did not markedly change gene expression. 
In the second part of this thesis, the molecular effects of psychopharmacologic drugs 
were profiled for their dependency on FKBP51 function to modulate intracellular 
pathways relevant for treatment outcome in a cellular FKBP5 knockout model. For this 
purpose, psychopharmaca from the classes of SSRIs, SSNRIs, TCAs, atypical 
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antidepressants, mood stabilisers, and NMDA receptor antagonists were analysed. In 
addition to GSK3β and AKT, which were reported to interact with and be targeted by 
FKBP51 recently (Gassen et al., 2015; Pei et al., 2009), ERK was identified as a novel 
kinase interacting with and being targeted by FKBP51 in this work. With GSK3β, AKT, 
and ERK, three major kinases were observed to be regulated by psychopharmaca. The 
effects were not homogeneous across all psychopharmaca and only loosely followed drug 
classes. Moreover, regulation of these kinases as well as their downstream targets was 
non-uniformly influenced by FKBP51. With FKBP51 being a stress induced gene, this 
transcriptional mechanism efficiently links the stress response to the regulation of the 
targets analysed in this work. Moreover, markers of autophagy, a cellular degradation 
process which has been linked to neurotransmission, were detected to be regulated by 
valproic acid (VPA), a mood stabiliser with HDAC inhibitory activity. VPA, as well as a 
second HDAC inhibitor butyric acid (BUT) enhanced the transcription of late and 
delayed autophagy markers controlled by FOXO3 signalling. 
Considering the versatile action of FKBP51 on targets analysed in this work, the list of 
proteins modulated by FKBP5 seems by far not complete. The diversity of effects evoked 
by different psychopharmaca hints to superimposed molecular effects underlying 
treatment outcome. Better understanding of pathway responsiveness could yield 
molecular markers for personalised medication that could be utilised to improve 
treatment outcome in stress related psychiatric diseases. 
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1 Introduction 
1.1 Physiology of stress disorders 
Depressive disorders have been ranked a leading cause of burden (Ferrari et al., 2013). 
Major depression is a serious and mostly recurrent disorder, strongly impairing quality of 
life (Ustün et al., 2004). Lifetime prevalence for people from high income countries is 
about 15 % (Kessler and Bromet, 2013). Major depression represents also an independent 
risk factor for other diseases like dementia, diabetes, cardiovascular disease and 
osteoporosis (Knol et al., 2006; Nicholson et al., 2006). 
1.1.1 Physiology of the stress reaction 
The term stress disorder already implies the fundamental influence of stress in the 
pathophysiology of a certain group of psychiatric disorders. Stress may arise from all 
kinds of environmental challenges of physical or psychological nature. In the classical 
stress concept, every organism needs to adopt to changes of the environment in order to 
ensure the perpetuation of homeostasis (Chrousos and Gold, 1992). Hence, sensing the 
stressor and directing the organism to a coping behaviour is an essential strategy of 
survival. In the concept of allostasis, these dynamic processes not only opt at restoring 
homeostasis but also include anticipatory mechanisms that prime the organism for future 
challenges (McEwen, 2000). Effective stress coping includes both the rapid activation of 
stress response as well as the efficient termination of the stress response afterwards. 
Overshooting and prolonged stress response, however, can lead to allostatic load and 
stress related disorders, such as anxiety, depression, schizophrenia or post-traumatic 
stress disorder (de Kloet et al., 2005).  
In mammals, the sensory information derived from a stressor is processed by limbic brain 
structures including the hippocampus, amygdala and the prefrontal cortex. The stress 
response itself is then mediated by a fine-tuned hormonal system, which is composed of 
hormone producing tissues in the hypothalamus, pituitary and adrenal gland and 
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therefore referred to as hypothalamic-pituitary-adrenal (HPA) axis. Upon perception of a 
stressor, the paraventricular nucleus of the hypothalamus is activated by the limbic 
system to synthesise and secrete corticotropin-releasing hormone (CRH) and vasopressin 
within minutes. One function of CRH is to activate the HPA axis-independent 
noradrenergic and sympathetic central nervous systems by innervation of the locus 
coeruleus (Valentino et al., 1983). On the pituitary level of HPA axis signalling, CRH is 
transported to the anterior lobe of the pituitary via the hypophyseal portal system, where 
it stimulates the secretion of adrenocorticotropic hormone (ACTH) into the circulatory 
system (Vale et al., 1981). Acting on the adrenal gland, ACTH exerts the synthesis and 
secretion of glucocorticoids from the adrenal cortex. This class of steroid hormones, 
which is mainly represented by cortisol in human and corticosterone in rodents, binds to 
intracellular steroid hormone receptors, especially the glucocorticoid receptor (GR) and 
the mineralcorticoid receptor (MR). Activating their receptors, GCs not only trigger 
adaptional processes in a variety of immunological and metabolic functions by changing 
gene transcription, but also act on the hypothalamus and the pituitary inhibiting the 
secretion of CRH and ACTH. This inhibitory mechanism provides a feedback loop for 
reducing the activity of the HPA axis and the termination of the stress response. 
1.1.2 The role of HPA axis dysregulation in stress disorders 
Malfunction in HPA-axis has been found in depressive patients, which has led to the 
definition of the stress hormone dysregulation hypothesis of depression (Holsboer, 2000). 
This hypothesis originates from clinical observations in depressive patients that show 
increased secretory pulses and elevated levels of the HPA-axis hormones CRH, ACTH 
and cortisol. These observations were complemented by monitoring the responsiveness 
of the HPA-axis with tests of neuroendocrine function, such as the dexamethasone 
suppression test, the CRH stimulation test and their combination. Diminished 
suppressibility of corticosteroids by administration of the synthetic glucocorticoid as well 
as decreased ACTH response after CRH injection are characteristic HPA-axis features in 
patients with various affective disorders. Moreover, normalisation of HPA axis activity 
appears to be crucial for therapeutic success in depressive patients (Holsboer et al., 
1987). 
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1.2 FKBP51 in the physiology of stress disorders 
Prolonged and excessive activation of the HPA-axis has been implicated in the 
pathogenesis of mood and anxiety disorders. Therefore, a healthy stress response requires 
its proper termination, which physiologically is realised via the GR dependent feedback 
loop acting on the hypothalamus and the pituitary. Of particular importance is hence the 
fine-tuned molecular system that regulates the activity of the GR (Holsboer, 2000; 
Pariante and Miller, 2001). 
1.2.1 FKBP51 as a regulator of HPA axis activity 
The GR is a transcription factor that regulates gene transcription when it is activated by 
its corticosteroidal ligands. Ligand bound GR shuttles from the cytosol into the nucleus 
and binds to specific DNA motifs. A switch in the composition of the chaperone complex 
that binds to the GR tightly controls this translocation and stimulation process (Grad and 
Picard, 2007). Chaperone complexes ensure the proper folding, maturation and 
conformation of their target proteins. The GR is associated with a complex of heatshock 
protein 70 (HSP70), heatshock protein 90 (HSP90) and a number of co-chaperones. In 
fact, the co-chaperone FK506 binding protein 51 (FKBP51; in this thesis this 
abbreviation is used for all species) has been found to play a major role in the regulation 
of the GR complex (Pratt and Toft, 1997).  
FKBP51 is a 51 kDa protein encoded by the FKBP5 gene. Together with cyclophilins, 
FK506 binding proteins (FKBPs) represent the immunophilin protein family named for 
their ability to bind immunosuppressive drugs. All immunophilins share the common 
feature of a domain with peptidyl prolyl isomerases activity that is able to catalyse the 
cis-trans conversion of peptidyl prolyl bonds (FK domain). In addition, FKBP51 is 
composed of a second FK (FK2) domain that differs slightly from the first FK (FK1) 
domain and lacks peptidyl prolyl isomerases and FK506 binding ability. C-terminally, 
FKBP51 provides a tetratricopeptide repeat (TPR) domain, a structural motif that binds 
to the EEVD motif at the extreme C-terminus of HSP90 (Sinars et al., 2003). 
A hint for the importance of FKBP51 in GR signalling was found by the discovery of a 
differentially regulated HPA axis in New World Monkeys. Compared to other monkeys 
and primates, intensely increased plasma cortisol levels have been found in these 
animals. Surprisingly, increased plasma cortisol levels are not accompanied by signs of 
hyper-cortisolism. The assumption of inhibited affinity of the GR to cortisol in New 
World Monkeys was substantiated by the detection of FKBP5 overexpression in these 
1.2 FKBP51 in the physiology of stress disorders 
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animals together with the elucidation of the role of FKBP51 in regulation of the GR 
complex (Scammell et al., 2001).  
FKBP51 as well as its close homolog FKBP52 bind to the GR HSP90 complex via their 
TPR domains. After hormone binding, FKBP51 is replaced by FKBP52, which facilitates 
nuclear translocation and gene transcription by recruiting dynein to the complex (Davies 
et al., 2005). Overexpression of FKBP5 has been shown to reduce hormone binding 
affinity and nuclear translocation of the GR by shifting the equilibrium of FKBP51 and 
FKBP52 associated hormone receptor complexes (Wochnik et al., 2005). 
Interestingly, the FKBP5 promoter comprises several intronic glucocorticoid response 
elements (GREs), which induce transcription upon GR activation (Hubler and Scammell, 
2004; U et al., 2004). By this bidirectional regulation, the GR is not only desensitised by 
the FKBP51 protein but also facilitates the transcription of FKBP5 thereby providing an 
ultra-short feedback loop in regulation of GR activity (Vermeer et al., 2003). Upon 
cortisol binding to the GR, FKBP51 is exchanged to FKBP52, which mediates dynein 
interaction, nuclear translocation, DNA binding and transcriptional activity of the GR. 
Besides the transcriptional activation of other targets, active GR induces FKBP5 
transcription and FKBP51 protein in turn conveys lower GR hormone sensitivity, which 
terminates the glucocorticoid activity. 
1.2.2 FKBP51 in the risk of stress related psychiatric disorders 
Based on this molecular evidence, FKBP5 was included as candidate in a genetic 
association study in major depression. This study provided first evidence for differential 
FKBP5 expression caused by variations in the FKBP5 gene (Binder et al., 2004). Single 
nucleotide polymorphisms (SNPs) in the FKBP5 gene were associated with high 
inducibility of FKBP5 transcription upon GR activity, the recurrence of depressive 
episodes and reduced HPA-axis hyperactivity during the depressive episode (Binder et 
al., 2004). Subsequently a lower sensitivity of the GR towards cortisol was found in 
individuals carrying the SNP associated with the high-induction FKBP5 allele (Binder et 
al., 2008). Furthermore, this baseline difference in GR sensitivity also affects hormone 
levels of a stress challenged HPA-axis. A genetic study in stressed healthy individuals 
showed an association of the highly inducible FKBP5 alleles with a delayed negative 
feedback represented as a significantly slower recovery from stress-related increases in 
cortisol levels (Ising et al., 2008).  
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Differences in allelic expression of FKBP5 might be explained by alterations of 
interaction of steroid receptors with the intronic GREs in the FKBP5 gene (Hubler and 
Scammell, 2004; U et al., 2004). Indeed, the SNP rs1360780 that is associated with 
increased FKPB5 expression is located less than 200 bp from the highly conserved GRE 
in intron 2 of the FKBP5 gene (Hubler and Scammell, 2004). 
These genetic association studies together with the molecular findings provide a 
mechanism how differences in the FKBP5 genes in the population could prime the 
individual risk for stress related psychiatric disorders in human. In its two partied 
function as a cortisol responsive gene on the one hand and a GR sensitivity regulating 
protein on the other hand, FKBP5 can integrate environmental influences onto genome 
activity and thus prime the risk for the development of stress related psychiatric 
disorders. Evidence for the hypothesis that FKBP5 alleles associated with slower return 
to baseline levels of stress induced cortisol levels increase the risk for stress related 
psychiatric disorders comes from studies both in mood and anxiety disorders. 
The strongest genetic evidence for the role of FKBP5 in stress related psychiatric 
disorders comes from post-traumatic stress disorder (PTSD), an anxiety disorder 
resulting from the exposure to a traumatic event. The SNPs rs3800373 and rs1360780 in 
FKBP5 are associated with the individual risk for increased peri-traumatic dissociation 
after medical trauma, a prediction factor for PTSD (Koenen et al., 2005; Ozer et al., 
2003). Moreover, a potential gene – environment interaction was found for PTSD 
patients with childhood trauma experience. The four SNPs rs9296158, rs3800373, 
rs1360780, and rs9470080 interacted with the severity of child abuse as a predictor of 
adult PTSD symptoms. Interestingly, there were no direct effects of the SNPs on PTSD 
symptoms and no significant genetic interactions with the level of non–child abuse 
trauma to predict adult PTSD symptoms (Binder et al., 2008). Childhood trauma in 
individuals with the high induction FKBP5 allele, however, appears to increase the risk 
for developing adult PTSD, potentially due to increased GR resistance.  
In PTSD patients, however, these same alleles were found to be associated with higher 
GR sensitivity, which itself is associated with PTSD symptoms (Binder et al., 2008; 
Yehuda et al., 2004). This hints to a context-dependent effect of the high induction alleles 
on GR sensitivity. Further support for this hypothesis comes from patients with PTSD 
that showed reduced FKBP5 mRNA expression, consistent with enhanced GR 
responsiveness (Yehuda et al., 2009). This environment dependent reversal of FKBP5 
function might be explained by epigenetic changes in the FKBP5 gene upon trauma 
exposure and thus provide a possible molecular framework of how gene – environment 
interaction shapes the risk for psychiatric disorders.  
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Besides post translational modification of histones, DNA methylation is one of the major 
epigenetic marks that alter chromatin structure and thus the accessibility of the DNA to 
transcriptional regulators. Especially changes in DNA methylation have been reported as 
long-lasting epigenetic consequences of early trauma (Murgatroyd et al., 2009). In 
addition, chronic activation of the GR has been shown to induce local changes in DNA 
methylation, inter alia, at relevant GREs in the FKBP5 locus (Lee et al., 2010). Finally, 
the observation that combined effects of early life stress and a functional polymorphism 
in the FKBP5 gene alter the risk for PTSD, provided an example for gene – environment 
interaction (Klengel et al., 2013). In FKBP risk allele carriers, excessive cortisol release 
following early life stress exposure led to stronger and stable demethylation around a 
specific GRE of FKBP5. This resulted in lasting disruption of the ultra-short feedback 
loop that balances FKBP5 and GR activity, which was accompanied by an increased risk 
for PTSD in later life. 
Associations between FKBP5 polymorphisms and mood disorders, however, are still 
inconsistent. An over-representation of the high induction alleles in unipolar depression, 
which was found in both a epidemiologic and a family study, could not be confirmed in 
several other studies (Binder et al., 2004; Gawlik et al., 2006; Lekman et al., 2008; Papiol 
et al., 2007; Willour et al., 2009). Disease specific characteristics like weak phenotype 
definitions and environmental induced disease heterogeneity may contribute to the lack 
of strong main genetic effects in genome wide association studies. Durable epigenetic 
changes induced by long term environmental effects, as described for PTSD above, 
might provide a mechanism that could explain missing heritability in mood disorders as 
well (Slatkin, 2009). 
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1.3 Pharmacological treatment of stress disorders 
Up to now, worldwide only a minority of people suffering from major depressive 
disorder receives treatment, and among those treatment outcome remains poor (Kessler, 
2012). Conventional medication is based on a hypothesis of pathophysiology developed 
in the 1960s. As discrepancies arose within this hypothesis on the one hand and treatment 
response rates remained poor on the other hand, novel pharmacological treatment 
approaches, however, came into focus (aan het Rot et al., 2009). Taken into account the 
genetic and environmental induced diversity of stress related psychiatric diseases, a 
personalised medication strategy would probably largely increase treatment success 
(Binder and Holsboer, 2006). In order to achieve this, progress has to be made in the 
characterisation of individual patients on the one hand, and the understanding of 
mechanism of action of current psychopharmaca as well as the identification of novel 
drug targets on the other hand. 
1.3.1 Treatment approaches based on the monoamine hypothesis 
The monoamine deficiency hypothesis, one of the earliest hypotheses of depression 
pathophysiology, stipulates a deficiency of noradrenergic, serotonergic and/or 
dopaminergic neurotransmitter in the synaptic cleft as causal factor for the 
pathophysiology of depression (Carlsson et al., 1968; Dunlop and Nemeroff, 2007; 
Schildkraut, 1965). Accordingly, rebalancing monoaminergic signalling with an 
antidepressant would tend to restore normal function in depressed patients. 
Historically, the monoamine deficiency hypothesis evolved when antidepressant side 
effects in tuberculosis patients treated with iproniazid were observed and inhibitory 
action of iproniazid on the monoamine oxidase was detected, which increased the 
concentration of norepinephrine in the synaptic cleft by blocking the degradation of 
monoamines (Zeller et al., 1952). Additionally, the depressogenic side effects of 
reserpine, a blocker of the vesicular monoamine transporter, supported the involvement 
of monoamines in depression (Everett and Tolman, 1959). Later on it was shown that the 
administration of imipramine and imipramine-like agents, early members of the group of 
tricyclic antidepressants (TCAs), increased norepinephrine concentration in the rodent 
brain by blocking its cellular uptake (Glowinski and Axelrod, 1964). In the following 
years also inhibition of serotonin reuptake was shown for imipramine (Carlsson et al., 
1968). Since then, several drugs with a tricyclic structure have received FDA approval, 
amongst them amitriptyline (AMT, doxepin (DXP) and clomipramine (CLP). 
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After to the promising results obtained with the MAOIs and TCAs, more selective 
reuptake-inhibitors for serotonin, norepinephrine and dopamine were identified. Finally 
in 1968, fluoxetine (FLX), one of the first selective serotonin reuptake inhibitors (SSRIs), 
became available on the market and achieved comparable antidepressant effects along 
with reduced side effects compared to TCAs (Montgomery, 1989). SSRIs are now the 
most widely prescribed group of antidepressants in many countries, typically used in the 
treatment of major depressive disorder and anxiety disorders (Preskorn et al., 2004). 
Most common SSRIs besides fluoxetine are citalopram (CTP), escitalopram, 
fluvoxamine, paroxetine (PRX) and sertraline. 
In 1993, venlafaxine (VNF), the first non-tricyclic agent with dual serotonin and 
norepinephrine reuptake inhibition (SNRIs), was introduced to the US market (Gutierrez 
et al., 2003). The accessory inhibition of norepinephrine reuptake might be causative for 
the potential of venlafaxine to induce a rapid onset of action in contrast to MAOIs, 
TCAs, and SSRIs (Ruelas et al., 1997). Additionally to venlafaxine, the most commonly 
used SNRI, duloxetine, desvenlafaxine and milnacipran became approved members of 
the group of SNRIs. Recently, vortioxetine (VTX) has been shown to not only inhibit the 
serotonin reuptake but to also act as partial agonist of the 5-HT1A receptor and antagonist 
of the 5-HT3 and 5-HT7 receptors (Mahableshwarkar et al., 2013). VTX has received 
FDA approval for the treatment of adults suffering from major depressive disorder in 
2013. 
The so called second-generation antidepressants with selective reuptake inhibition 
profiles for serotonin, norepinephrine and dopamine have since then gradually replaced 
first-generation antidepressants such as MAOIs and TCAs, mostly because of their 
improved tolerability and safety profile (Spina et al., 2008). 
1.3.2 Treatment approaches beyond the monoamine system 
It turned out that the monoamine deficiency hypothesis does not cover all the effects 
antidepressants exert in a biological system. For example the atypical antidepressant 
tianeptine (TNP), structurally belonging to the group of TCAs, decreases the extracellular 
monoamine concentration but coinstantaneously exerts antidepressant effects (Lôo et al., 
2001). Furthermore, it remains unclear why not all drugs that enhance serotonergic or 
noradrenergic transmission are necessarily effective in the treatment of depression. 
Moreover, the monoamine deficiency hypothesis failed to provide reasonable models for 
the delayed beneficial effect in patients in contrast to the rapid boost in available 
monoamines within hours (Gardner and Boles, 2010). 
1.3 Pharmacological treatment of stress disorders 
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Recently, non-monoaminergic biological systems have received increasing attention as 
potential drug targets in the treatment of mood disorders, amongst them aminoacid 
neurotransmitter receptors and transporters, neuropeptides and neurotrophic factors 
(Mathew et al., 2008). Especially the observation that the anaesthetic ketamine (KTM), 
an NMDA receptor antagonist, has potent antidepressant effects when administered in a 
single subanesthetic dose has driven attention to the glutamatergic and dopaminergic 
signalling (Duman et al., 2012; Zarate et al., 2006). Effort has been made to find more 
selective NMDA receptor antagonists and several substances are in clinical trials now. 
One of those substances, Lanicemine (LNC), can produce rapid antidepressant effects in 
subjects with treatment-resistant major depressive disorder without psychomimetic side 
effects like ketamine (Zarate et al., 2013). 
A further class of drugs is used especially for the treatment of bipolar disorder, a subtype 
of depression characterised by periods of elevated mood and periods of depression. 
Already more than half a century ago, psychiatric patients were treated with lithium 
carbonate (LIT), which was reported to cease or reduce symptoms in manic patients 
(Cade, 1949). In parallel to the introduction of the first SSRIs in the late 1960s, clinical 
evidence was provided for the effectiveness of LIT therapy in bipolar affective disorder 
(Baastrup and Schou, 1967). Potential mechanism of LIT action include ion 
dysregulation, effects on neurotransmitter signalling, inhibition of glycogen synthase 
kinase 3 beta (GSK3β), interaction with the adenylyl cyclase system as well as inositol 
and protein kinase C signalling (Marmol, 2008). 
Evidence has also been provided for the effectiveness of lamotrigine (LMT), a 
phenyltriazine derivative used for anticonvulsant medication as a mood stabiliser; LMT 
has been the first FDA approved drug for this purpose since the approval of LIT almost 
30 years earlier (Goldsmith et al., 2003). Approved for treatment of mania in the US in 
1995, valproate has since then surpassed LIT as the primary mood stabiliser prescribed 
for the treatment of bipolar disorder. Several mechanisms of action of valproate that may 
be relevant to its actions in bipolar disorders have been reported. These include inhibition 
of GSK3β and activation of extracellular signal-regulated kinase (ERK) (Einat et al., 
2003; Yuan et al., 2001). Interestingly, several of these actions overlap with those 
observed for LIT (Harwood and Agam, 2003).  
Moreover, VPA has been shown to modulate the epigenome by inhibiting histone 
deacetylases (HDACs) and DNA methyltransferase (DNMT) (Göttlicher et al., 2001; 
Zimmermann et al., 2012). Antidepressant-like effects have been found for HDAC 
inhibitors (Covington et al., 2009; Schroeder et al., 2007; Tsankova et al., 2006). 
1.3 Pharmacological treatment of stress disorders 
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Reversal of dysfunctional epigenetic regulation associated with early life events might 
thus play a role in the mood stabilizing effects of VPA.  
1.3.3 FKBP51 as modulator of antidepressant responsiveness 
While psychopharmaca are widely prescribed to treat stress-related psychiatric disorders, 
response to medication is highly variable with only some patients responding to a 
particular treatment. Besides clinical heterogeneity, diagnostic uncertainty and 
environmental and social factors, the genetic and epigenetic configuration of individual 
patients might provide explanations for the poor drug-response rates. 
First evidence for a role of FKBP5 in antidepressant treatment response came from a 
genetic study, which found association of three SNPs in this gene with antidepressant 
treatment outcome in depressed patients of two independent samples (Binder et al., 
2004). Patients homozygous for the high-induction FKBP5 alleles responded faster to 
treatment with either TCAs or SSRIs. A meta-analysis including data from eight genetic 
association studies, however, could not validate the association between SNPs rs1360780 
and rs3800373 with treatment response, but confirmed a significant association of SNP 
rs4713916 and response rate in patients with mood disorders (Zou et al., 2010). 
The finding that reduced HPA axis hyperactivity after treatment in patients carrying the 
genotypes associated with faster response alleles combined with the observation that the 
high induction alleles associated with enhanced GR sensitivity in depressed patients hint 
to a mechanism where FKBP51 facilitates the normalization of HPA axis hyperactivity 
upon treatment.  
Mechanistic evidence for an FKBP5 dependent treatment response beyond the 
hypothesised normalization of HPA axis hyperactivity is provided by two of our recent 
studies. We could show that the protein FKBP51 is required for the effects of both acute 
and chronic antidepressant treatment on behaviour and on autophagic pathways in mice 
(Gassen et al., 2014). Furthermore we identified the early stages of autophagy as FKBP5 
modulated targets of antidepressants. In a second study we found that deletion of FKBP5 
attenuated the behavioural effects of LIT treatment in mice (Gassen et al., 2015). 
Summarised, these findings point to a multifactorial role of FKBP51 in modulation of 
treatment response via several pathways targeted by antidepressant drugs. 
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1.4 Potential cellular pathways affected by FKBP5 and 
stress or antidepressants 
Exposure to chronic stress has been shown to affect brain morphology, neurogenesis, 
synaptic transmission and structural plasticity, amongst other in the hippocampus (Joëls 
et al., 2008). Effort has been made to clarify the underlying pathways without gaining a 
clear picture up to now. At least some of the stress effects can be targeted with 
antidepressant treatment (Warner-Schmidt and Duman, 2006). 
1.4.1 Transcriptional pathways 
Transcriptional analysis in models of chronic stress consistently found modifications in 
the expression of brain-derived neurotrophic factor, cAMP-response-element binding 
protein, serotonin receptors, HPA axis components, synaptic proteins, transcription 
factors and proteins involved in neuronal growth and differentiation (Alfonso et al., 
2005). Only a minority of the changes could be reversed by blockade of glucocorticoid 
receptor signalling (Datson et al., 2012). In general, however, these alterations could be 
reversed by treatment with antidepressants (Alfonso et al., 2005). The particular role of 
the stress induced protein FKBP51 in regulation of global gene expression, however, has 
not been addressed so far. At least in its function as a modulator of glucocorticoid 
induced transcription, FKBP51 should be a regulator of gene transcription. 
1.4.2 GSK3β signalling 
GSK3β is a serine-threonine kinase that was primarily identified as a glycogen synthase 
inhibiting enzyme, a key player in energy homeostasis (Cohen and Frame, 2001). Over 
the years, it became more and more evident that GSK3β plays an important role in 
developmental processes in the brain, including neurogenesis and neuroprotection (Hur 
and Zhou, 2010). Regulation of the processes involves the kinase activity of GSK3β onto 
its wide network of target proteins. GSK3β is a constitutively active kinase and becomes 
inactivated upon phosphorylation at its N-terminus at Ser-9 (Harwood, 2001). Several 
kinases including AKT, protein kinase A and protein kinase C as well as the two 
phosphatases protein phosphatase 2A and protein phosphatase 1 have been shown to 
control Ser-9 phosphorylation of GSK3β (Harwood, 2001). 
1.4 Potential cellular pathways affected by FKBP5 and stress or antidepressants 
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Increased GSK3β activity is observed as a pathogenic factor and normalisation of GSK3β 
activity is considered as therapeutic means in bipolar disorder and schizophrenia 
(Emamian, 2012; Jope and Roh, 2006). In line, increased activity of GSK3β along with 
decreased activity of AKT, was found post-mortem in the ventral prefrontal cortex of 
subjects with major depression (Karege et al., 2007). Accordingly, several mood 
stabilisers, antidepressants and antipsychotics inhibit GSK3β (Li and Jope, 2010). 
Furthermore, we recently could show that FKBP51 inhibits GSK3β and auguments the 
effects of distinct psychotropic medications (Gassen et al., 2015). 
A prominent target of GSK3β is β-catenin (BCAT), which primarily has been 
characterised as an intracellular signal transducer in the Wnt signaling pathway. In this 
regard, BCAT is phosphorylated by GSK3β at an ubiquitin ligase recognition motif, 
thereby promoting its proteasomal degradation (Xing et al., 2003). Interestingly, chronic 
treatment with lithium, a well-known inhibitor of GSK3β, has been shown to increase 
brain β-catenin levels in rodents (De Ferrari et al., 2003). 
Another target of GSK3β is collapsin response mediator protein 2 (CRMP2), which plays 
an important role in neuronal polarization (Ip et al., 2014). In addition, activity of 
CRMP2 has been associated with psychiatric diseases and in particular with 
schizophrenia (Fallin et al., 2005; Yoshimura et al., 2005). Activity of CRMP2 is 
precisely regulated by phosphorylation status of CRMP2. GSK3β phosphorylates 
CRMP2 at the Thr-509 and Thr-514 sites in the presence of a priming phosphorylation at 
Ser-522 (Yoshimura et al., 2005). When phosphorylated at Thr-514, interaction of 
CRMP2 with tubulin is reduced, which leads to inhibition of neurite extension 
(Yoshimura et al., 2005). 
1.4.3 Autophagy 
An important pathway affected by antidepressants is autophagy (Rossi et al., 2009; 
Zschocke et al., 2011). It is an evolutionary conserved cellular process that controls the 
functional integrity of cells via the degradation of damaged cytoplasmic proteins and 
organelles (Mizushima and Komatsu, 2011). The subtype of autophagy reported to be 
affected by antidepressants is macroautophagy. It is characterised by the engulfment of 
autophagic cargo by membranous structures leading to the formation of autophagosomes, 
which subsequently fuse with a protease-providing lysosome.  
The initiation of autophagy is mediated by the ULK1 complex, which serves as a hub for 
the integration of upstream signals to the downstream PI3K effector complex (Alers et 
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al., 2012). Activation of ULK1 results in the phosphorylation of Beclin-1 (BECN1) and a 
subsequent increase in the activity of the VPS34 complex (Russell et al., 2013). We 
recently could show, that the autophagy and apoptosis regulating phosphorylation of 
BECN1 by AKT is dependent on FKBP51 (Gassen et al., 2014; Wang et al., 2012). 
Autophagosome formation is tightly controlled by a series of autophagy proteins (ATGs). 
Precursor vesicles containing a complex of ATG5 - ATG12 - ATG16L1 fuse to form a 
sac-like single membrane covered pre-autophagosomal structure called phagophore (Puri 
et al., 2013). Important for the recruitment of membrane to the growing phagophore is 
the incorporation and processing of microtubule-associated protein 1 light chain 3 (LC3) 
into the membrane. LC3 is, in a first step, cleaved to form LC3-I and in a second step 
conjugated to phosphatidylethanolamine to form LC3-II (Kabeya et al., 2000). LC3-II 
remains associated with the closing membrane globe that imbeds substrates for 
degradation. Furthermore LC3 plays a role in the recruitment of the adaptor protein p62 
(Noda et al., 2008). Upon maturation and fusion of the autophagosomes with lysosomes, 
the autophagic substrates become digested and recycled. 
An additional level of autophagy regulation is represented by transcriptional control of 
the ATG genes via members of the family of forkhead box O (FOXO) transcription 
factors. Especially FOXO3α is involved in promoting autophagy upon nutrient 
deprivation (Sengupta et al., 2009). Activity of FOXO3α is mainly regulated by 
phosphorylation, amongst others at Ser-256, Ser-318 and Ser-321 by AKT (Rena et al., 
2002). When phosphorylated, FOXO3α is exported from the nucleus and thus becomes 
transcriptionally inactive.  
1.4.4 ERK signalling 
The Extracellular Signal-regulated Kinases ERK1 and ERK2 belong to the family of 
mitogen-activated protein kinases, that play a role in various cellular processes such as 
proliferation, differentiation, survival and apoptosis (Sun et al., 2015). Moreover, it was 
also reported that the ERK pathway plays a role in AMPK induced autophagy regulation 
via BECN1 (Wang et al., 2009). Recently, also an unconventional regulation of ERK 
phosphorylation by autophagic ATG proteins as cellular scaffolds was reported 
(Martinez-Lopez et al., 2013). Furthermore, ERK has been shown to inhibit FOXO3α via 
phosphorylation at Ser-294, Ser-344 and Ser-425 (Yang et al., 2008). 
ERK activity itself is tightly regulated by the dual specificity mitogen-Activated Protein 
kinases 1 AND 2 via phosphorylation at Thr-202 and Thr-204 (Rubinfeld and Seger, 
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2005). Because of the high similarity of their sequences, it has long been a matter of 
debate whether ERK1 or ERK2 are functionally redundant (Lefloch et al., 2009). 
In the last decade,  ERK signalling has been implicated in depression (Duric et al., 2010; 
Dwivedi et al., 2001; Einat et al., 2003; Qi et al., 2009). Furthermore, differential effects 
of antidepressant treatment on ERK phosphorylation were reported (Di Benedetto et al., 
2013; Fumagalli et al., 2005; Zassadowski et al., 2015). However, cell type, treatment 
duration and drug class appear to be important factors determining the changes in ERK 
phosphorylation. 
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1.5 Objective 
FKBP51 is a major regulator of the GR and shapes its hormone affinity. This mechanism 
has been shown to be important for the regulation of the mammalian stress response and 
to be implicated in the pathophysiology of stress related psychiatric disorders. Effects of 
FKBP51 on kinases were also reported recently. 
1.5.1 Does FKBP5 modulate transcription of risk genes? 
The first objective of this thesis was to analyse FKBP5 dependent effects on global gene 
transcription in an unbiased approach. Differential transcriptional effects may be induced 
by FKBP51 either directly via regulation of GR mediated transcription or indirectly 
through yet largely unknown pathways, conceivably through the wide effects on kinase 
activity. The aim was to compare the expression profile of FKBP5-KO and FKBP5-WT 
mice and in the next step to characterise the regulation of differentially expressed genes. 
Those genes would be considered additional candidates potentially underlying the 
pathophysiology of psychiatric disorders. 
1.5.2 Do different psychopharmaca affect overlapping pathways 
subjected to FKBP5? 
In a second study, the impact of several psychopharmaca from different drug groups on 
selected pathways was to be analysed on the protein level. In order to unravel a potential 
effect of FKBP5 on the induction of the protein markers by those psychopharmaca, 
embryonal fibroblast cells deficient of FKBP5 as well as wild type equivalents were to be 
utilised. 
Prior to this study, it was published that FKBP51 interacts with the kinase AKT and 
modulates its phosphorylation status by recruiting PHLPP phosphatase (Pei et al., 2009). 
Further evidence for a global role of FKBP51 in modulating kinase activity was provided 
by a screening experiment that showed that FKBP51 is present in several HSP90 
dependent client complexes, in particular in HSP90:kinase complexes (Taipale et al., 
2010). Given the clinical observation that FKBP5 impacts on the antidepressant response, 
molecular pathways affected both by FKBP5 and psychopharmaca were searched for. 
FKBP5 dependent action of psychopharmaca on molecular markers could provide a 
mechanism for the role of FKBP51 in antidepressant response. In two recent publication 
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we could show that the proteins AKT, BECN1 and GSK3β are convergently targeted by 
FKBP51 and the psychopharmaca PRX and LIT (Gassen et al., 2014, 2015). 
Interestingly, AKT as well as GSK3β have both already been discussed as 
psychopharmaca targets downstream of the D2 dopamine receptor (Beaulieu et al., 
2009).  
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2 Material 
2.1 Consumable supplies 
 
Type Manufacturer 
Cell culture dishes, multi-well plates TPP (Trasadingen, Switzerland) 
Cell scrapers sterile Peske (Aindlingen-Arnhofen) 
Centrifugation tubes 50 mL, 15 mL  TPP (Trasadingen, Switzerland) 
Cryotubes 2 mL TPP (Trasadingen, Switzerland) 
Electroporation cuvettes Bio-Rad Laboratories (München) 
Eppendorf reaction tubes 1.5 mL, 2 mL  TPP (Trasadingen, Switzerland) 
Eppendorf reaction tubes 1.5 mL, low-binding Eppendorf (Wesseling-Berzdorf) 
Eppendorf reaction tubes 1.5 mL, safe-lock  Eppendorf (Wesseling-Berzdorf) 
Filter paper 3 MM Whatman  Carl Roth (Karlsruhe) 
Folded filter Carl Roth (Karlsruhe) 
Glass slides  Carl Roth (Karlsruhe) 
Luminometer plate 96 well (white) Nalgene Nunc International (USA) 
Nitrocellulose membrane  GE Healthcare (Freiburg) 
Pasteur pipettes 230 mm Carl Roth (Karlsruhe) 
Petri dishes unsterile TPP (Trasadingen, Switzerland) 
Pipette Stripette 1, 5, 10, 25 mL Corning Inc. (Acton, USA) 
Pipette tips 0.5-10 µL, 5-200 µL, 100-1000 µL Corning Inc. (Acton, USA) 
Plastic supplies for tissue culture  TPP (Trasadingen, Switzerland) 
Serological pipettes 2, 5, 10, 25 mL Peske (Aindlingen-Arnhofen) 
Table 1: List of consumable supplies. 
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2.2 Chemicals and solutions 
 
Type Manufacturer 
Acetic acid (CH3COOH) Sigma-Aldrich (St. Louis, USA) 
Acrylamide/Bis Solution, 37.5:1 (30% w/v) Serva (Heidelberg) 
Adenosine 5‘-triphosphate (ATP) Sigma-Aldrich (St. Louis, USA) 
Agar agar Carl Roth (Karlsruhe) 
Agarose Biozym (Oldenburg) 
AhR Inhibitor αNaphtovlavone Sigma-Aldrich (St. Louis, USA) 
Amitriptyline hydrochloride Sigma-Aldrich (St. Louis, USA) 
Ammonium sulfate Carl Roth (Karlsruhe) 
Ammonium persulfate (APS)  Carl Roth (Karlsruhe) 
Ampicillin Sigma-Aldrich (St. Louis, USA) 
Antibiotic-antimycotic (100x) Life Technologies (Carlsbad, USA) 
Bafilomycin A1 Sigma-Aldrich (St. Louis, USA) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich (St. Louis, USA) 
Brilliant blue G Sigma-Aldrich (St. Louis, USA) 
Bromophenol blue  Sigma-Aldrich (St. Louis, USA) 
Calcium chloride (CaCl2 · 2 H2O) Carl Roth (Karlsruhe) 
Citalopram hydrobromide Sigma-Aldrich (St. Louis, USA) 
Clomipramine hydrochloride Sigma-Aldrich (St. Louis, USA) 
Coenzyme A Sigma-Aldrich (St. Louis, USA) 
Coomassie Brillant Blue G  Sigma-Aldrich (St. Louis, USA) 
Deoxynucleotide triphosphates (dNTPs)  Peqlab (Erlangen) 
Dexamethasone Sigma-Aldrich (St. Louis, USA) 
Dipotassium phosphate (K2HPO4 · 3 H2O) Carl Roth (Karlsruhe) 
Disodium phosphate (Na2HPO4) Carl Roth (Karlsruhe) 
DME medium Life Technologies (Carlsbad, USA) 
DMSO (dimethyl sulfoxide)  Sigma-Aldrich (St. Louis, USA) 
Doxepine hydrochloride Kemprotec (Cumbria, U.K.) 
DTT (1,4-Dithiothreitol)  Carl Roth (Karlsruhe) 
Ethanol absolute p.a. Sigma-Aldrich (St. Louis, USA) 
Ethidium bromide Sigma-Aldrich (St. Louis, USA) 
Ethylene glycol tetraacetic acid (EGTA) Carl Roth (Karlsruhe) 
Fetal bovine serum Life Technologies (Carlsbad, USA) 
Fluoxetine hydrochloride Sigma-Aldrich (St. Louis, USA) 
Gentamycine Life Technologies (Carlsbad, USA) 
Glucose Carl Roth (Karlsruhe) 
Glycerol Merck Millipore (Darmstadt) 
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Type Manufacturer 
Glycin Sigma-Aldrich (St. Louis, USA) 
GSK3 Inhibitor CHIR99021 Merck Millipore (Darmstadt) 
Hydrochloric acid (HCl) Merck Millipore (Darmstadt) 
IGEPAL Sigma-Aldrich (St. Louis, USA) 
Isopropyl alcohol Sigma-Aldrich (St. Louis, USA) 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG)  Peqlab (Erlangen) 
Ketamine Sigma-Aldrich (St. Louis, USA) 
Lamotrigine  Sigma-Aldrich (St. Louis, USA) 
Lanicemine hydrochloride Kemprotec (Cumbria, U.K.) 
Lithium chloride Sigma-Aldrich (St. Louis, USA) 
Magnesium chloride (MgCl2) Carl Roth (Karlsruhe) 
Magnesium sulfate (MgSO4) Merck Millipore (Darmstadt) 
Methanol Sigma-Aldrich (St. Louis, USA) 
Milk powder Carl Roth (Karlsruhe) 
MTT dye Sigma-Aldrich (St. Louis, USA) 
Paraformaldehyde (PFA) Carl Roth (Karlsruhe) 
Paroxetine hydrochloride Sigma-Aldrich (St. Louis, USA) 
PBS (10x) Life Technologies (Carlsbad, USA) 
Phosphoric Acid, 85% Sigma-Aldrich (St. Louis, USA) 
PMSF (Phenylmethylsulfonyl fluoride) Sigma-Aldrich (St. Louis, USA) 
Poly-D-lysine  Sigma-Aldrich (St. Louis, USA) 
Potassium acetate Carl Roth (Karlsruhe) 
Potassium chloride (KCl) Carl Roth (Karlsruhe) 
Potassium hydroxide (KOH) Carl Roth (Karlsruhe) 
Ribonuclease A Sigma-Aldrich (St. Louis, USA) 
S.O.C. medium Life Technologies (Carlsbad, USA) 
Sodium butyrate (BUT) Sigma-Aldrich (St. Louis, USA) 
Sodium chloride (NaCl) Carl Roth (Karlsruhe) 
Sodium dodecyl sulfate (SDS)  Fluka (USA) 
Sodium hydroxide (NaOH) Merck Millipore (Darmstadt) 
Sodium pyruvate (100x) Life Technologies (Carlsbad, USA) 
TEMED (Tetramethylethylenediamine)  Carl Roth (Karlsruhe) 
Tianeptine Kemprotec (Cumbria, U.K.) 
Trichostatin A (TSA) Sigma-Aldrich (St. Louis, USA) 
Tris-(hydroxymethyl)-aminomethane (Tris)  Riedel-de Haen (Seelze) 
Triton X-100  Carl Roth (Karlsruhe) 
Trypan blue (5x) Carl Roth (Karlsruhe) 
Trypsin-EDTA solution (10x) Life Technologies (Carlsbad, USA) 
Tween 20  Sigma-Aldrich (St. Louis, USA) 
2.3 Buffer and self-made media 
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Type Manufacturer 
Valproic Acid Sigma-Aldrich (St. Louis, USA) 
Venlafaxine hydrochloride Kemprotec (Cumbria, U.K.) 
Vortioxetine hydrobromide Sigma-Aldrich (St. Louis, USA) 
β-Mercaptoethanol Sigma-Aldrich (St. Louis, USA) 
Table 2: List of chemicals and solutions. 
2.3 Buffer and self-made media 
 
Amaxa electroporation buffer 
90 mM Sodium phosphate 
5 mM KCl 
0.15 mM CaCl2 
50 mM Hepes 
 pH adjusted to 7.3 
 
Bacterial freezing medium 
50 % Glycerol 
50 % LB medium 
 
CoIP buffer 
20 mM Tris-HCl, pH 8.0 
100 mM NaCl 
1 mM EDTA 
0.5 % Igepal 
1 x Protease inhibitor cocktail (Sigma, P2714) 
 
5 x DNA loading buffer 
5 % Glycerol 
0.5 % SDS 
10 mM EDTA 
0.025 % Bromophenol blue 
0.025 % Xylene cyanol 
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FLuc buffer (optimised) 
40 mM Tris-HCl 
15 mM MgSO4 
4 mM EGTA 
0.2 mM Coenzyme A 
2 mM DTT 
1 mM ATP 
0.2 mM Luciferin 
 pH adjusted to 7.8 with HCl 
 
FLuc buffer (traditional) 
3 mM MgCl2 
2.5 mM ATP 
0.2 mM Luciferin 
 
Freezing medium 
40 % DMEM 
50 % FCS 
10 % DMSO 
 
GenePulser electroporation buffer 
50 mM Potassium phosphate, pH 7.35 
20 mM KAc, pH 7.35 
25 mM MgSO4, pH 6.7 
 
PLP 
0.2 % Triton X-100 
100 mM Potassium phosphate, pH 7.8 
 
solubilisation buffer 
20 % (w/v) SDS 
50 % (v/v) DMF 
50 % (v/v) H2O 
 pH adjusted to 2.0 with HCl 
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RLuc buffer 
1.1 M NaCl 
2.2 mM EDTA 
220 mM Potassium phosphate 
0.44 g/l BSA 
5.72 µM Coelenterazine 
 pH adjusted to 5.1 with HCl 
 
S1 buffer 
50 mM Tris-HCl 
10 mM EDTA, pH 8.0 
100 µg/µl RNase A 
 
S2 buffer 
200 mM NaOH 
1 % SDS 
 
S3 buffer 
2.8 M KAc, pH 5.1 
 
TBE buffer 
9 mM Boric acid 
0.25 mM EDTA 
9 mM Tris-HCl 
 pH adjusted to 8.3 
 
TfB I 
30 mM KAc, pH 8.5 
100 mM RbCl 
50 mM MnCl2 
10 mM CaCl2 
15 % Glycerol 
 pH adjusted to 5.8 
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TfB II 
10 mM MOPS-KOH, pH 6.8 
100 mM RbCl 
75 mM CaCl2 
15 % Glycerol 
 pH adjusted to 6.5 
2.4 Kits and ready-to-use materials 
 
Type Manufacturer 
Albumin Standard Thermo Scientific (Rockford, USA) 
BCA Protein Assay Thermo Scientific (Rockford, USA) 
BSA (100x) for restriction of DNA NEB (Frankfurt) 
Dynabeads Protein G Life Technologies (Frankfurt) 
EndoFree Plasmid Maxi Kit Qiagen (Hilden) 
EZ-PCR Mycoplasma Test Kit Biological Industries (Frankfurt) 
GeneArt Site-Directed Mutagenesis System Life Technologies (Frankfurt) 
Genomic DNA from Tissue Macherey-Nagel (Düren) 
Immobilon ECL reagent Merck Millipore (Darmstadt) 
LDH Cytotoxicity Detection Kit Clontech (Paris, France) 
NEBuffers 1-4 for restriction of DNA NEB (Frankfurt) 
NucleoBond AX100 Columns Macherey-Nagel (Düren) 
peqGOLD DNA ladder mix Peqlab (Erlangen) 
peqGOLD Prestained Protein-Marker IV  Peqlab (Erlangen) 
Protease inhibitor cocktail Sigma-Aldrich (St. Louis, USA) 
QIAquick Gel Extraction Kit  Qiagen (Hilden) 
RNA isolation kit Macherey-Nagel (Düren) 
Table 3: List of kits and ready-to-use materials. 
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2.5 Cloning enzymes 
 
Type Manufacturer 
Herculase II Fusion DNA Polymerase Agilent Technologies (Santa Clara, USA) 
Restriction Endonucleases NEB (Frankfurt) 
T4-DNA Ligase NEB (Frankfurt) 
Taq DNA Polymerase Life Technologies (Frankfurt) 
Table 4: List of cloning enzymes. 
2.6 Antibodies 
2.6.1 Primary antibodies 
 
Type Manufacturer 
Anti-Actin Santa Cruz Biotech. (Heidelberg) 
Anti-Akt Cell Signaling (Cambridge, U.K.) 
Anti-BCAT BD Biosciences (Franklin Lakes, USA) 
Anti- BECN1 Cell Signaling (Cambridge, U.K.) 
Anti-CRMP2 Cell Signaling (Cambridge, U.K.) 
Anti-pCRMP2(T514) Cell Signaling (Cambridge, U.K.) 
Anti-ERK1 Cell Signaling (Cambridge, U.K.) 
Anti-Fkbp51 Bethyl Laborat. (Montgomery, USA) 
Anti-Fkbp52 Bethyl Laborat. (Montgomery, USA) 
Anti-Flag Biomol (Hamburg) 
Anti-FoxO3a Cell Signaling (Cambridge, U.K.) 
Anti-Glo1 Santa Cruz Biotech. (Heidelberg) 
Anti-GSK3b Cell Signaling (Cambridge, U.K.) 
Anti-HA Roche (Basel, Switzerland) 
Anti-Hsp90 Santa Cruz Biotech. (Heidelberg) 
Anti-JunB Cell Signaling (Cambridge, U.K.) 
Anti-LC3 Cell Signaling (Cambridge, U.K.) 
Anti-MEK1 Cell Signaling (Cambridge, U.K.) 
Anti-Myc Sigma-Aldrich (St. Louis, USA) 
2.7 Bacterial clades 
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Type Manufacturer 
Anti-pAkt(S473) Cell Signaling (Cambridge, U.K.) 
Anti-pERK1/2(T202/Y204) Cell Signaling (Cambridge, U.K.) 
Anti-pFoxO3a(S318/S321) Cell Signaling (Cambridge, U.K.) 
Anti-pGR(S211) Sigma-Aldrich (St. Louis, USA) 
Anti-pGR(S226) Sigma-Aldrich (St. Louis, USA) 
Anti-pGSK3b(S9) Cell Signaling (Cambridge, U.K.) 
Anti-pJunB(S259) Cell Signaling (Cambridge, U.K.) 
Anti-pMSK1(T581) Cell Signaling (Cambridge, U.K.) 
Anti-pRSK1(T359/S363) Merck Millipore (Darmstadt) 
Anti-pSGTA(S305) Cell Signaling (Cambridge, U.K.) 
Table 5: List of primary antibodies. 
2.6.2 Secondary antibodies 
 
Type Manufacturer 
Donkey anti-goat Alexa Fluor 488 Life Technologies (Frankfurt) 
Goat anti-mouse HRP Santa Cruz Biotech. (Heidelberg) 
Goat anti-rabbit HRP Santa Cruz Biotech. (Heidelberg) 
Table 6: List of secondary antibodies. 
2.7 Bacterial clades 
 
Type Genetic description 
E. coli BL21(DE3)pLysS B F- dcm ompT hsdS(r B-;m B-) galß(DE3)[pLysS Cam`] 
E. coli DH5α F-Ф80LacZΔM15Δ(lacZYA-argF)U169 deoR recA1 endA1 hsdR17 (r k-
;m r+) phoA supE44 thi-1gyrA96relA1 
Table 7: List of bacterial clades 
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2.8 Cell lines 
 
Type origin 
HEK-293 Human kidney cells 
HeLa Human cervix carcinoma cells 
MEF Mouse embryonal fibroblasts 
MEF-FKBP51-/- Mouse embryonal fibroblasts from FKBP51-/- animals 
Table 8: List of cell lines. 
2.9 Oligonucleotides 
 
Name Sequence (5’ – 3’) Purpose 
actin 1as CAGGTCCAGACGCAGGATGGC qRT 
actin 1s CTACAATGAGCTGCGTGTGGC qRT 
Atg12_M_RT_1_fw AACAAAGAAATGGGCTGTGGAGCG qRT 
Atg12_M_RT_1_rv TTCCGAGGCCACCAGTTTAAGGAA qRT 
Becn1_M_RT_1_fw TGAAATCAATGCTGCCTGGG qRT 
Becn1_M_RT_1_rv CCAGAACAGTATAACGGCAACTCC qRT 
FKBP51_H_RT_f CCATTGCTTTATTGGCCTCT qRT 
FKBP51_H_RT_r GGATATACGCCAACATGTTCAA qRT 
Fkbp51-M-RT-for TGCAGATCTCCATGTGCCAGAGG qRT 
Fkbp51-M-RT-for_2 AGCAACGGTAAAAGTCCACCT qRT 
Fkbp51-M-RT-rev GCTCCTTCTACAGCCTTCTTGCTCC qRT 
Fkbp51-M-RT-rev_2 CCCAACAACGAACACCACATC qRT 
Fkbp51Ex2-fw AAAGGACAATGACTACTGATGAGG genotyping 
Fkbp51Int2/3-re AAGGAGGGGTTCTTTTGAGG genotyping 
Fkbp51WT-M-RT-f CCATGACTGAGCAGGGTGAAG qRT 
Fkbp51WT-M-RT-r CCAAACATTGGGGCCTCGTC qRT 
FKBP52_H_RT_f CATTGCCATAGCCACCATGAA qRT 
FKBP52_H_RT_r TCCAGTGCAACCTCCACGATA qRT 
FKBP5-HR-f_1 ACCAAAGAAAAACTGGAGCAGGC qRT 
FKBP5-HR-r_1 GTAGCACATGGCCAGGTTGAG qRT 
GAPDH_H_RT_f AATGGGCAGCCGTTAGGAAA qRT 
GAPDH_H_RT_r ACCAGAGTTAAAAGCAGCCC qRT 
2.9 Oligonucleotides 
 
27 
 
Name Sequence (5’ – 3’) Purpose 
GAPDH_M_RT_f TCCATGACAACTTTGGCATTGTGG qRT 
GAPDH_M_RT_r GTTGCTGTTGAAGTCGCAGGAGAC qRT 
LC3B_M_RT_1_fw TCGCCGACCGCTGTAAG qRT 
LC3B_M_RT_1_rv CTCGATGATCACCGGGATCT qRT 
GLO1-H-RT-f_1 TCCCCGCCATGATTCACATT qRT 
GLO1-H-RT-f_2 TCTTCCCCGCCATGATTCAC qRT 
GLO1-H-RT-r_1 AGCAGTACAAGCACGGTTGG qRT 
GLO1-H-RT-r_2 AGTACAAGCACGGTTGGCAT qRT 
GLO1-R-RT-f_1 TCTTGGACTGACGCTTCTCC qRT 
GLO1-R-RT-r_1 TGTCCTCTCCGTCTTGTCCT qRT 
GLO1-R-RT-r_2 GAGCTCCAGGGTAGCCTTTC qRT 
Glo1-RT-for TGCCGTTCCTGATGTCTACAGTGCC qRT 
Glo1-RT-rev TCCCCCATACCTCAAAGGCACATTC qRT 
GR_H_seq1_f TACCACAGACCAAAGCACCTT seq 
GR_H_seq2_r TCCGGTAAAATGAGAGGCTT seq 
GR1-515_pEGFP_f CTACAGGAGTCTCACAAGAAACCTCTGAAAATCCT
TGAGGTACCGCGGGCCCGGGATCCACCGGATCTAG 
cloning 
GR1-515_pEGFP_r CTAGATCCGGTGGATCCCGGGCCCGCGGTACCTCA
AGGATTTTCAGAGGTTTCTTGTGAGACTCCTGTAG 
cloning 
GR1-515_pRK7_f CTACAGGAGTCTCACAAGAAACCTCTGAAAATCCT
TGACTGCCTTAATAAGAATGGTTGCCTTAAAGAAA 
cloning 
GR1-515_pRK7_r TTTCTTTAAGGCAACCATTCTTATTAAGGCAGTCAA
GGATTTTCAGAGGTTTCTTGTGAGACTCCTGTAG 
cloning 
GR-A211_f AGGTCTGATCTCCAAGGAGCCTCATTCGTCTCTTTA
C 
mutation 
GR-A211_r GTAAAGAGACGAATGAGGCTCCTTGGAGATCAGAC
CT 
mutation 
GR-A226_new_f TTCTCCCGCCAGAGGAGCAAGCAAACAGTTTTCAT
C 
mutation 
GR-A226_new_r GATGAAAACTGTTTGCTTGCTCCTCTGGCGGGAGA
A 
mutation 
GR-E211_f AGGTCTGATCTCCAAGGCTCCTCATTCGTCTCTTTA
C 
mutation 
GR-E211_r GTAAAGAGACGAATGAGGAGCCTTGGAGATCAGA
CCT 
mutation 
GR-E226_f TTCTCCCGCCAGAGGCTCAAGCAAACAGTTTTCATC mutation 
GR-E226_r GATGAAAACTGTTTGCTTGAGCCTCTGGCGGGAGA
A 
mutation 
HPRT R+M as CCTGTATCCAACACTTCGAG qRT 
HPRT R+M s AACGGGGGACATAAAAGTTA qRT 
HPRT_H_RT_f TTGCTTTCCTTGGTCAGGCA qRT 
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Name Sequence (5’ – 3’) Purpose 
HPRT_H_RT_r TTCGTGGGGTCCTTTTCACC qRT 
NPSR1-CNV_f CAGCTGCTGCCCCGGCTAAC gDNA 
NPSR1-CNV_r GGTTGGCTGGCATGGCTCAGG gDNA 
GLO1-CNV_f CTCTGCCCCAGAGAACAGTC gDNA 
GLO1-CNV_r TGATAGAGGCCACACAGCAG gDNA 
ULK1_M_RT_1_fw TGCCCTTGATGAGATGTTCC qRT 
ULK1_M_RT_1_rv AGTCTCCTCTCAATGCACAGC qRT 
VPS34_M_RT_1_fw TGTCAGATGAGGAGGCTGTG qRT 
VPS34_M_RT_1_rv CCAGGCACGACGTAACTTCT qRT 
Table 9: List of oligonucleotides. 
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Name Feature Source Backbone 
ERK1-HA expression of HA-tagged ERK1 in 
mammalian cells 
Plasmid obtained 
from addgene.org 
pMT 
FHRE-FLuc FLuc under control of Foxo3a 
responsive promoter 
Plasmid obtained 
from addgene.org 
 
FKBP51-FLAG expression of FLAG-tagged FKBP51 
in mammalian cells 
Plasmid obtained 
from addgene.org 
 
Gaussia-KDEL SV40-driven gaussia luciferase 
reporter plasmid 
Plasmid obtained 
from G. Wochnik 
pRK5 
GR(A211)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
GR(A211)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR(A211,A226)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
GR(A211,A226)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR(A211,E226)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
GR(A211,E226)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR(A226)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
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Name Feature Source Backbone 
GR(A226)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR(E211)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
GR(E211)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR(E211,A226)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
GR(E211,A226)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR(E211,E226)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
GR(E211,E226)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR(E226)-GFP expression of point-mutated GFP-
tagged GR in mammalian cells 
subcloned from 
GR-GFP 
pEGFP 
GR(E226)-HA expression of point-mutated HA-
tagged GR in mammalian cells 
subcloned from 
GR-HA 
pRK7 
GR-GFP expression of GFP-tagged GR in 
mammalian cells 
Plasmid obtained 
from G. Wochnik 
pEGFP 
GR-HA expression of HA-tagged GR in 
mammalian cells 
Plasmid obtained 
from G. Wochnik 
pRK7 
MMTV-FLuc FLuc under control of MMTV 
promoter 
Plasmid obtained 
from G. Wochnik 
 
pRK5-SV40-MCS Cloning vector for protein expression 
in mammalian cells. 
Plasmid obtained 
from G. Wochnik 
pRK5 
TCF/LEF-FLuc FLuc under control of TCF/LEF 
responsive promoter 
Plasmid obtained 
from addgene.org 
 
Table 10: List of plasmids. 
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Name Manufacturer 
Allegra 21 Beckman (Krefeld) 
Allegra X-22R Beckman (Krefeld) 
Axioplan 2 Carl Zeiss (Jena) 
Balance Voyager 50187 Ohaus (Giessen) 
Biofuge pico Heraeus (Mannheim) 
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Name Manufacturer 
Centro Luminometer Berthold Tech. (Bad Wildbad) 
ChemiDoc Imaging System Bio-Rad Laboratories (München) 
CK30 Olympus (Hamburg) 
Electroporation System, Gene Pulser II Bio-Rad Laboratories (München) 
High-voltage power supply PowerPac 400 Bio-Rad Laboratories (München) 
Incubator CB210 Binder (Tuttlingen) 
IX50 Olympus (Hamburg) 
J2 MC (Rotor JA-14) Beckman (Krefeld) 
LSM FV1000 Olympus (Hamburg) 
Magnetic stirrer RCT basic IKAMAG Labortechnik (Staufen) 
Microplate reader MR 7000 Dynatech (Denkendorf) 
Mini Trans-Blot Cell Bio-Rad Laboratories (München) 
Mini-PROTEAN Electrophoresis system Bio-Rad Laboratories (München) 
Overhead stirrer Rotamix ELMI (Latvia) 
pH meter pH538 WTW (Weilheim) 
Pipettes PIPETMAN Gilson (Middletown, USA) 
Refrigerated centrifuge (5417 R) Eppendorf (Wesseling-Berzdorf) 
Refrigerated centrifuge (5804 R) Eppendorf (Wesseling-Berzdorf) 
Sonicator, Cell Disruptor B15 Branson (USA) 
Spectrophotometer DU 640 Beckman (Krefeld) 
Stirrer DUOMAX 1030/POLYMAX1040 Heidolph (Schwabach) 
Supplies for agarose gels Bio-Rad Laboratories (München) 
Thermocycler Primus 25 Peqlab (Erlangen) 
Thermocycler Tgradient Biometra (Göttingen) 
Thermomixer comfort Eppendorf (Wesseling-Berzdorf) 
TriStar LB941 Luminometer Berthold Tech. (Bad Wildbad) 
TSC SP5 Leica (Solms) 
Ultracentrifuge LB-70M (Rotor: SW 60 Ti) Beckman (Krefeld) 
UV-Transilluminator Stratagene (La Jolla, USA) 
UV-Transilluminator GelDoc Bio-Rad Laboratories (München) 
Varifuge 3.0R Heraeus (Mannheim) 
Vortexer MS2 IKA Labortechnik (Staufen) 
Voyager 50228 (Precision balance) Ohaus (Giessen) 
Water bath type 1008 Ges. f. Labortechnik (Burgwedel) 
Table 11: List of instruments. 
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2.12 Software 
 
Name Application 
Adobe Acrobat 8.0 Creating and editing pdf-files 
Gimp 2.8 Image processing 
Image Lab 5.0 Device control and data analysis for ChemiDoc imaging system 
Inkscape 0.48 Vector graphic design 
MikroWin 2013 Device control and data analysis for Tristar plate reader 
MS Office 2013 Office suite for desktop application 
Sigma Plot 12.5 Statistical analysis 
Table 12: List of software. 
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3 Methods 
3.1 Bacterial culture 
3.1.1 Culturing and storage of bacteria 
Escherichia coli (E. coli) bacteria of the clades DH5α and BL21 were streaked on agar 
plates with semi-solid medium to generate discrete colonies. Antibiotics ampicillin or 
kanamycin was added to the medium in a final concentration of 100 μg/ml or 25 μg/ml 
respectively in order to select for cells containing the plasmid of choice. Liquid cultures 
containing antibiotics were inoculated with a single colony or directly from glycerol 
stocks and cultured on a shaker at 200 rpm. Bacteria were cultured in LB medium at 
37 °C. Optical density of liquid cultures was measured in a photometer at 550 nm to 
determine bacteria concentration. Cells were harvested at 3200 g at 4 °C for 10 min. 
Storage of bacteria was achieved by re-suspending the pellet of a fresh 5 ml overnight 
culture in 1 ml bacterial freezing medium. The glycerol stocks were stored at -80 °C. 
3.1.2 Preparation of competent cells 
Competent cells are needed for incorporation of plasmid DNA. Chemically competent 
bacterial cells of the strain DH5α were generated as follows: Cells were grown in 5 ml 
LB medium overnight. 5 ml pre-culture was transferred into 400 ml LB medium and 
cultivated until an optical density of 0.48 was reached. Cells were harvested by 
centrifugation at 3200 g at 4 °C for 5 min and re-suspended in 10 ml TfB I buffer. After 
10 min incubation cells were again harvested at 5000 rpm at 4 °C for 5 min. Cells were 
subsequently re-suspended in 2 ml TfB II buffer, aliquoted and frozen in liquid nitrogen. 
Cells were stored at -80 °C. 
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3.1.3 Transformation of competent cells 
Transformation of competent DH5α was carried out by the heat shock method. 15 μl of 
ligation reaction or 5 to 25 ng plasmid DNA was added to 50 μl of competent bacteria 
solution thawed on ice before. The mixture was incubated on ice for 30 min. Afterwards 
heat shock was applied at 42 °C for 45 s followed by cooling on ice for 10 min. Bacteria 
were rescued in SOC medium for 60 min at 37 °C under constant shaking of 400 rpm. 
Finally bacteria were streaked on agar plates containing antibiotic selecting for 
transformed bacteria and incubated at 37 °C overnight. 
3.1.4 Isolation of plasmid DNA from bacteria 
Preparation of plasmid DNA from bacteria was performed in two scales: with 5 ml 
overnight bacterial cultures for mini preparation scale and 50 ml for midi preparation 
scale. Both protocols were performed with alkaline lysis of the bacteria. 
For mini preparation 2 ml of a fresh overnight culture was centrifuged for 5 min at 5000 
rpm. Pellet cells were re-suspended in 200 μl buffer S1. Cells were lysed by addition of 
200 μl buffer S2, inverting the tube 6 times and incubation at room temperature for 
5 min. 200 μl of neutralisation buffer S3 was added, the solution was mixed by inverting 
the tube 6 times and incubated on ice for 5 min. Cell debris and genomic DNA was 
separated from the plasmid DNA by centrifugation for 30 min at 13000 rpm. Plasmid-
containing supernatant was transferred to a new tube, 500 μl of isopropanol was added 
and the mixture was centrifuged 5 min at 13.000 rpm in order to precipitate plasmid 
DNA. Plasmid DNA was washed by addition of 1 ml 70 % ethanol and centrifugation 
5 min at 13000 rpm. Ethanol was removed and the pellet was air-dried for about 30 min. 
plasmid DNA was re-suspended in 50 μl dH2O and stored at -20 °C. 
For midi preparations of plasmid DNA a fresh overnight culture was lysed and the 
plasmid DNA was clarified using anion-exchange columns (Macherey-Nagel, Düren) 
following the manufacturer´s instructions. Plasmid DNA pellet was re-suspended in 
about 100 μl dH2O and stored at -20 °C. 
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3.2 Cloning 
3.2.1 Polymerase chain reaction (PCR) 
In-vitro amplification of DNA fragments was carried out via polymerase chain reaction 
(PCR). All fragments required for cloning were amplified by Herculase II fusion DNA 
polymerase exhibiting proofreading activity. For analytical purposes fragments were 
amplified by Taq polymerase without proofreading function. 
For sub-cloning, the PCR reaction was prepared in a total reaction volume of 50 μl with 
the following components: 20 ng vector DNA template, 20 pmol of each primer, 200 μM 
of each dNTP, and 2.5 U Herculase II in 1 x reaction buffer. The temperature program 
for the PCR reaction catalysed by Herculase II was performed as follows: After an initial 
denaturation step, where the PCR mix was heated for 2 min at 95 °C, a three-stage 
temperature cycle was started and repeated for 25 to 30 times. This temperature cycle 
consisted of first a 30 s denaturation step at 95 °C, second a 30 s primer annealing step 
5 °C below the melting temperature of primers and third an elongation step at 68 °C. The 
duration of the elongation step was determined by the length of the fragments. At the 
very end a 5 min lasting elongation step at 68 °C was carried out to elongate incomplete 
fragments. 
For analytical purposes, vector DNA was amplified in 25 μl reaction volume with the 
following components: 10 ng DNA template, 10 pmol of each primer, 200 μM each 
dNTP, 5 mM MgCl2, and 1 U Taq polymerase in 1 x reaction buffer. The temperature 
program for PCR reaction catalysed by Taq polymerase fusion was performed as follows: 
After an initial denaturation, where the PCR mix was heated for 5 min at 95 °C, a three 
stage temperature cycle was started and repeated 30 times. This temperature cycle 
consisted first of a 60 s denaturation step at 95 °C, second a 60 s primer annealing step 
5 °C below the melting temperature of the primers and third an elongation step at 72 °C, 
whose duration was determined by the length of the fragment. Finally, a 5 min elongation 
step at 72 °C was carried out. 
3.2.2 Agarose gel electrophoresis 
Linear DNA fragments were separated according to their size by agarose gel 
electrophoresis. The size of the fragments was determined by comparison with a DNA 
ladder running on the same gel.  
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For gel preparation 1 to 1.5 g/l agarose was melted in 1 x TBE buffer by heating. After 
cooling down to about 40 °C, 0.1 μg/ml ethidium bromide was added. The solution was 
poured into a gel tank and a comb was inserted. To run the electrophoresis, the 
polymerised gel was transferred into the electrophoresis tank filled with TBE buffer. The 
DNA samples were mixed with 5x DNA loading buffer and carefully loaded into the 
wells. Electrophoresis was performed at 100 V until DNA fragments were separated. 
Afterwards the gels were analysed and dissected under UV irradiation of 302 nm in a 
UV-trans-illuminator (Stratagene). 
3.2.3 Purification of DNA from agarose gels 
In order to isolate particular DNA fragments separated by gel electrophoresis, gel bands 
containing the DNA were cut out from the gel on a UV-trans-illuminator with a scalpel. 
The DNA was purified from the gel with the QIAquick Gel Extraction Kit, subsequently 
eluted in 30 to 50 μl dH2O and stored at -20 °C. 
3.2.4 Enzymatic restriction of DNA 
For preparing the ends of DNA fragments for ligation or for vector analysis, plasmid 
DNA was cut using restriction endonucleases. The reaction was carried out under 
appropriate buffer conditions. BSA was added as recommended by NEB guidelines. For 
preparative restriction, 50 μl PCR product was reacted for 3 h at 37 °C in a 200 μl 
reaction volume containing 20 U of restriction endonucleases in the appropriate buffer 
conditions. For vector analysis, 5 μg of DNA was restricted for 90 min at 37 °C in a 25 μl 
reaction volume containing 10 U of restriction endonucleases in the appropriate buffer 
conditions. 
3.2.5 Ligation of DNA fragments 
Linear DNA fragments with complementary overhangs were ligated using T4 DNA 
ligase. Ligation was performed in a total reaction volume of 20 μl containing 0.025 pmol 
vector DNA, 0.075 pmol insert DNA and 1 μl T4 DNA ligase in 1 x reaction buffer at 
16 °C overnight. Subsequently, the product was immediately transformed into bacteria or 
stored at -20 °C. 
3.2 Cloning 
 
36 
  
3.2.6 Measurement of DNA concentration 
The concentration of nucleic acids was determined photometrically by measuring the 
absorbance at 260 nm in a quartz crystal cuvette. Potential protein contaminations was 
excluded by measuring the ratio of absorbance at 260 nm to 280 nm. 
3.2.7 Plasmid DNA sequencing 
The coding sequence as well as parts of the vector backbone was sequenced by 
Microsynth (Lindau). For this, the DNA was adjusted with dH2O to a concentration of 
80 ng/μl in a final volume of 10 µl. Primers were added in 20 pmol if needed. 
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3.3 Cell line culture 
3.3.1 Culturing of eukaryotic cell lines 
All cell lines used in this work were cultured as adherent cells in sterile tissue culture 
dishes or flasks. HEK-293 cells, HeLa cells or MEF cells were cultured in high glucose 
DMEM supplemented with 10 % FCS, 1 % sodium pyruvate and 1 % antibiotic-
antimycotic (penicillin-streptomycin) if not denoted differently. Cells were cultured in an 
incubator at 37 °C and under an atmosphere containing 5 % CO2. 
For maintenance, cells were passaged as soon as they had grown to an approximately 
90 % confluent population. For this, the adherent cells from a t-75 flask were carefully 
washed with 5 ml pre-warmed PBS once, then detached off the surface by incubating in 
2 ml pre-warmed trypsin-EDTA not more than 5 min. 3 ml DMEM were added to 
inactivate trypsin-EDTA. Cells were flushed from the surface and transferred to a sterile 
falcon tube. To remove the trypsin-EDTA, the cells were pelleted 4 min at 150 g and re-
suspended in an appropriate volume of fresh medium to split in the desired ratio. 
3.3.2 Storage of eukaryotic cell lines 
For the long-term storage of cell lines, the cell pellet of a confluent T-75 flask was re-
suspended in 1 mL freezing medium. The cell suspension was transferred to a cryo-tube 
and frozen overnight at -80 °C. For long term storage, the cells were placed in a liquid 
nitrogen tank at the next day.  
In order to take frozen cells into culture, the cells were thawed rapidly in a 37 °C water 
bath. The freezing medium was removed by centrifugation for 4 min at 150 g and re-
suspension in fresh culture medium. The cells were then transferred to a T-75 flask, 
incubated at 37 °C overnight and passaged on the next day. 
3.3.3 Transfection of eukaryotic cell lines 
For transfection of HEK-293 cells by electroporation, 5×106 cells were trypsinated, 
washed with PBS and electroporated with 10 µg plasmid DNA in 400 µl of GenePulser 
electroporation buffer using a GenePulser (Bio-Rad) at 350 V / 700 µF and cultivated as 
desired. 
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For chemo-transfection of HEK-293 cells in 96 well format, 10000 cells per well were 
seeded out 24 prior to transfection. For transfection of cells in one well, pre-mixes of 
300 ng plasmid DNA in 15 µl serum-free DMEM and 1 µl polyethylenimine (PEI, kindly 
provided by Dr. Heinrich Leonhardt, LMU, Munich) in 15 µl serum-free DMEM were 
mixed and transferred onto cells after an incubation step for 30 min at room temperature. 
For transfection of MEF cells by electroporation, 2x106 cells were trypsinated, washed 
with PBS and electroporated with 2 µg plasmid DNA in 100 µl of Amaxa electroporation 
buffer using the Amaxa Nucleofactor (Lonza) at T-020 setting and cultivated as desired. 
3.3.4 Genotyping of FKBP5 deficient MEF cells 
To obtain DNA, cells were trypsinated, pelleted by centrifugation for 4 min at 150 g and 
frozen at -20 °C if necessary. Next, 100 µl of 50 mM NaOH was added to the cell pellet 
and the mixture was boiled at 99°C for 30 min. The lysate was neutralised with 30 µl of 
1 M Tris-HCl with a pH of 7 and stored at -20 °C if not used immediately. Finally, 
genotypes were determined by PCR using primers surrounding the deleted region. 
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3.4 DNA-analytical methods 
3.4.1 Isolation of total RNA from tissues or cells 
Total RNA was isolated using an RNA isolation kit (Machery-Nagel) following the 
manufacturers instruction. Isolation of RNA based on cell lysis and RNase inactivation in 
a solution containing large amounts of chaotropic ions and adsorption of RNA to a silica 
membrane. Co-adsorbed DNA was removed by rDNAse dependent degradation. After 
washing and elution from the silica membrane, RNA was stored at -80 °C or immediately 
used for reverse transcription. 
3.4.2 Reverse transcription of RNA 
A reverse transcriptase was used to transcribe RNA from tissue or cells into coding DNA 
(cDNA). Reverse transcription reaction mix in a total volume of 20 µl was set up from 
400 ng RNA template, 2 µl 10x Omniscript RT-buffer (Qiagen), 500 nM each dNTP, 
2.5 µM random hexa-primers (Promega), 10 U RNase inhibitor and 4 U Omniscript 
reverse transcriptase (Qiagen). Reverse transcription was performed at 37 °C for 60 min. 
cDNA solution was stored at -20 °C. 
3.4.3 Isolation of genomic DNA from cooked mouse tails 
Isolation of genomic DNA from cooked mouse tails was performed using the Genomic 
DNA from Tissue kit (Macherey Nagel) as follows. Mouse tails were transferred to 
96 well plates, cooked in 100 µl 50 mM NaOH for 30 min and neutralised with 30 µl 
1 M Tris-HCl, pH7.0. 50 µl supernatant was transferred to a new reaction tube. Cell lysis, 
DNA binding to the column, washing and elution was performed exactly to the 
manufacturer’s instructions.  
3.4.4 Quantitative transcriptional real time PCR  
Gene expression was quantified using quantitative transcriptional real time PCR 
(qRT-PCR). Sections of interest in cDNA were amplified during PCR and synthesised 
double stranded DNA was quantified in real time as a measure of fluorescence light 
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emitted from the DNA intercalating fluorescent dye SYBR Green. Gene expression of a 
gene of interest was then calculated as the mean cycle number from exponential 
fluorescence signal increase and normalised to the same measure derived from analysis 
of a housekeeping genes. 
PCR reaction mix in a total volume of 10 µl was set up from 5 µl 2x QuantiFast SYBR 
Green PCR Master Mix (Qiagen), 10 pmol of forward and reverse primer and 2 µl of 
1:10 diluted cDNA. Reaction mixes were transferred to glass capillaries, centrifuged and 
analysed in a LightCycler 2.0 (Roche) in technical duplicates. The PCR programme 
started with 5 min incubation at 95 °C followed by 40 cycles of amplification (10 s at 
95 °C, 20 s at 60 °C). The fluorescence signal after each cycle was stimulated at 494 nm 
and measured at 521 nm. Specificity of the amplification was controlled by the existence 
of a single peak in the melting curve of the PCR product. 
3.4.5 Quantitative genomic real time PCR  
Quantitative genomic real time PCR was used to identify the copy number of a genomic 
region of interest, in this case a region suspected to be duplicated. The duplicated region 
was amplified during PCR with primers located in close proximity of the duplication 
boundary. Newly synthesised double stranded DNA was quantified in real time as a 
measure of fluorescence light emitted from the DNA intercalating fluorescent dye SYBR 
Green. The copy number was then calculated as mean cycle number of exponential 
fluorescence signal increase in section of interest relatively to the signal increase in a 
section of a housekeeping gene. 
PCR reaction mix in a total volume of 10 µl was set up from 5 µl 2x QuantiFast SYBR 
Green PCR Master Mix (Qiagen), 10 pmol of forward and reverse primer and 40 ng 
genomic DNA. Reaction mixes were transferred to glass capillaries, centrifuged and 
analysed in a LightCycler 2.0 (Roche) in technical duplicates. PCR programme started 
with 5 min incubation at 95 °C followed by 40 cycles of amplification (10 s at 95 °C, 
20 s at 60 °C). The fluorescence signal after each cycle was stimulated at 494 nm and 
measured at 521 nm. Specificity of the amplification was controlled by the existence of a 
single peak in the melting curve of the PCR product. 
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3.5 Protein-biochemical methods 
3.5.1 BCA assay for measurement of protein concentration 
Protein concentration was determined using a commercially available BCA kit (Thermo 
Scientific) and used according to the manufacturer´s instructions. The BCA reaction is a 
combination of the Biuret reaction where Cu2+ is reduced to Cu1+ in the presence of 
protein in an alkaline solution. Highly specific detection of Cu1+ in purple complexes 
with bichinonic acid (BCA) is used for absorbance photometry. Estimation of protein 
concentration is based on the comparison with BCA reacted in the presence of different 
amounts of bovine serum albumin (BSA) as standard. 
Samples as well as standards were pipetted into a 96-microtiter plate in triplicates. All 
samples and standards were mixed with the BCA reagent according to the manufacturer´s 
protocol and incubated at 60 °C for 20 min. The absorbance was measured at 550 nm in a 
microplate reader (Bio-Rad). 
3.5.2 SDS-Polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is used to separate proteins 
according to their molecular weight. Proteins are denatured and masked with the anionic 
detergent SDS, which carries a negative charge. By this, proteins are charged according 
to their size and can be separated in an electric field. To achieve optimal resolving 
conditions a discontinuous gel electrophoresis was used.  
Gels were poured in a gel caster (Bio-Rad) with a thickness of 1 mm. First, the resolving 
gel was poured into the apparatus and covered with a thin layer of isopropanol. After 20-
30 min isopropanol was removed, the stacking gel was poured onto the resolving gel and 
a comb was placed to form the slots. Polymerised gels were stored at 4 °C in a humid 
atmosphere. 
Protein solutions were boiled in Laemmli loading buffer at 95 °C for 5 min and 
subsequently loaded on the gel placed in the running chamber and filled with Laemmli 
running buffer. 
Electrophoresis was performed at 80 V for 20-30 min until the proteins were focused at 
the gel interface and at 150 V until the running front reached the end of the resolving gel. 
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After SDS-PAGE, the gels were used for subsequent detection of proteins in gel or 
western blotting on nitrocellulose membrane. 
3.5.3 Western Blotting 
Proteins separated by SDS-PAGE were immobilised on a nitrocellulose membrane by 
western blotting. For wet blotting, the transfer apparatus was assembled with the 
following components from cathode to anode in a sandwich manner: a sponge, three 
Whatman filter papers, gel, the nitrocellulose membrane, three Whatman papers and a 
sponge. All components were equilibrated in wetblot transfer buffer and the entire stack 
was placed into a blotting chamber filled with wetblot buffer. The transfer reaction was 
performed at 100 V for 90 min at 4 °C. 
3.5.4 Western Detection 
Proteins immobilised on a membrane were visualised by immuno-detection. If not 
denoted differently, two antibodies were used sequentially for this purpose. The primary 
antibody bound specifically to the target protein, while the secondary antibody, which 
was either coupled to the horseradish peroxidase (HRP) or a fluorescent dye, recognised 
the constant region of the primary antibody.  
Western detection was either carried out by a chemo-luminescent reaction catalysed by 
the HRP or by fluorescence derived from the coupled dye. For the sooner, HRP catalysed 
the oxidation of its substrate luminol in the presence of H2O2 resulting in a striking blue 
glow. For the latter, the fluorescent signal was measured. Both chemo-luminescence as 
well as fluorescence were detected in the ChemiDoc imaging system (Bio-Rad). 
Prior to the incubation with antibodies, non-specific binding sites on the nitrocellulose 
membrane were blocked by incubation in TBS-T supplemented with 5 % (w/v) milk 
powder for 1 h at room temperature. Subsequently, the membrane was incubated with the 
primary and secondary antibody. The membrane was incubated with primary antibodies 
diluted in TBS-T at 4 °C over night and with secondary antibodies diluted in TBS-T 
supplemented with 2 % (w/v) milk powder for 4 h at room temperature. After each 
antibody incubation the membrane was washed at least three times for 5 min with 
TBS-T. 
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3.6 Cellular assays 
3.6.1 MTT cytotoxicity assay 
Cytotoxicity was measured in a colorimetric assay determining cell metabolic activity. 
Viable, metabolically active cells produce reduction equivalents that reduce the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) dye to its insoluble, purple 
formazan salt, which shows an absorbance maximum near 570 nm. The quantity of 
formazan is presumably directly proportional to the number of viable cells and was 
measured by recording absorbance at 570 nm. 
Cells were seeded and treated in 96 well plates with 150 µl medium per well. For 
analysis of cytotoxicity 75 of cell culture medium was removed and 25 µl MTT dye 
(2 mg/ml in PBS) was added to the adherent cells covered with 75 µl remaining cell 
culture medium and incubated for 6 hours at 37 °C. Formazan salt was solubilised by 
incubation with 100 µl solubilisation buffer per well over night in a dark place at room 
temperature. Formazan dependent absorption was measured at 570 nm.  
3.6.2 LDH cytotoxicity assay 
Cytotoxicity can also be measured as a means of membrane integrity. The release of the 
widely expressed intracellular enzyme lactate dehydrogenase (LDH) into the cell culture 
medium is quantified by a coupled enzymatic reaction. In a first step, LDH catalyses the 
conversion of lactate to pyruvate via reduction of NAD+ to NADH. Second, NADH 
dehydrogenase uses NADH to reduce a tetrazolium salt to a red formazan product. The 
quantity of formazan is presumably directly proportional to the amount of released LDH 
and was measured by recording absorbance at 490 nm. 
Cells were seeded and treated in 96 well plates in 150 µl per well cell culture medium 
supplemented with only 1 % serum. Maximal cytotoxicity as reference value was 
achieved by incubation with 1 % Triton X-100. For analysis of cytotoxicity 75 µl of cell 
culture medium from treated cells was transferred to a new 96 well plate and mixed with 
75 µl LDH substrate (LDH Cytotoxicity Detection Kit, Clontech). After light protected 
incubation for 30 min at room temperature absorbance was measured at a wavelength of 
490 nm. 
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3.6.3 Dual luciferase assay in MEF cells 
MEF cells were transfected by electroporation and seeded out into 64 wells of a 96 well 
plate per electroporation cuvette. For TCF/LEF responsive reporter gene assays, the 
amounts of transfected plasmids electroporation cuvette were 1.2 µg luciferase based 
TCF/LEF responsive reporter plasmid TOPFlash, 0.6 µg FLAG-tagged FKBP51 
expression plasmid, and 0.2 µg of Gaussia-KDEL expression vector as control plasmid. 
For FoxO responsive reporter gene assays, the amounts of transfected plasmids 
electroporation cuvette were 1.0 µg luciferase based FoxO responsive reporter plasmid 
FHRE, 0.8 µg FLAG-tagged FKBP51 expression plasmid, and 0.2 µg of Gaussia-KDEL 
expression vector as control plasmid. 24 h after transfection, cells were cultured for 48 h 
in fresh medium supplemented with drugs as indicated or DMSO as control.  
To measure reporter gene activity cells were washed once with PBS and lysed in 50 µl 
passive lysis buffer (PLP). Firefly and Gaussia luciferase activities were measured in the 
same aliquot using an automatic luminometer equipped with an injector device (Tristar, 
Berthold). Firefly activity was measured first by adding 50 μl FLuc buffer (optimised) to 
10 µl lysate in white microtiter plates. By adding 50 µl RLuc buffer the firefly reaction 
was quenched and Gaussia luminescence was measured after a 5 s delay. Firefly activity 
data represent the ratio of background corrected Firefly to Gaussia luminescence values. 
3.6.4 Co-immunoprecipitation 
Co-immunoprecipitations (CoIPs) were performed in HEK-293 cells. 72 hours after 
transfection by electroporation, cells were lysed in CoIP buffer. This was followed by 
incubation on an overhead shaker for 20 min at 4 °C. The lysate was cleared by 
centrifugation for 20 min at 13000 g at room temperature. 1.2 mg of lysate was incubated 
with 2.5 µg of the target directed antibody overnight at 4 °C on an overhead rotator. 20 µl 
of BSA-blocked Protein G Dynabead slurry (Invitrogen, 100-03D) was added to the 
lysate-antibody mix, followed by 3 h of incubation at 4 °C. The beads were washed three 
times with PBS, and protein-antibody complexes were eluted with an excess of antigen 
peptide in CoIP buffer for 30 min at 4°C. 5 to 15 µg of the cell lysates or 2.5 µl of the 
immunoprecipitates were separated by SDS-PAGE and analysed by western detection. 
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4 Results 
4.1 Transcriptional regulation by FKBP51 
FKBP5 is a mediator of the stress response system and plays an important role in the 
development of stress-related diseases. To elucidate the role of FKBP5 in an animal 
model, a knockout mouse had been constructed (Touma et al., 2011). These mice had 
been generated following the well-established technique of replacing the endogenous 
allele by a non-functional allele employing in vitro homologous recombination in stem 
cells isolated from a blastocyst, a procedure herein referred to as conventional gene 
knockout. Offspring homozygous for the FKBP5 deletion showed an enhanced negative 
glucocorticoid feedback at the HPA axis in response to a chronic stress paradigm, 
indicative of an increased sensitivity of the GR (Hartmann et al., 2012). On the 
behavioural level, they displayed more active coping behaviour upon either chronic or 
acute stress (Hartmann et al., 2012; Touma et al., 2011). To elucidate the effects of 
FKBP5 deletion on molecular pathways the expression profile of stressed mice deficient 
for FKBP5 (FKBP5-KO) and their wild type litter mates (FKBP5-WT) was compared. 
4.1.1 Expression analysis in FKBP5-KO mice 
For this purpose, six FKBP5-WT and six FKBP5-KO mice were treated with 
dexamethasone for three hours by intraperitoneal injection of 2 mg/kg. mRNA 
expression of whole brain lysates were analysed on two Illumina gene expression arrays, 
covering 45281 gene probes. 
Within a 95 % confidence interval, four genes were detected differentially expressed 
between dexamethasone treated FKBP5-KO mice and their dexamethasone treated 
FKBP-WT litter mates (Figure 1). Besides downregulation of FKBP5, increased 
expression of the three genes RNA binding motif protein 12 (RBM12), glyoxalase 1 
(GLO1) and faciogenital dysplasia 2 (FGD2) was detected.  
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The first gene, RBM12, codes for a protein of unknown function. The protein contains 
five distinct RNA binding motifs, two proline-rich regions and several putative 
transmembrane domains (Stover et al., 2001).  
 
Gene FC  Adj.P.Val 
FKBP5 -2.1  0.00004 
RBM12 1.6  0.0285 
GLO1 1.7  0.0313 
FGD2 1.9  0.0428 
Figure 1: Specification of the four top genes across the FKBP5 genotype contrast as detected by 
the microarray expression analysis. Genes with adjusted p-values smaller than 0.05 are listed. 
The second gene, GLO1, is a ubiquitously expressed enzyme that catalyses the 
isomerization of hemithioacetal adducts. Thus, GLO1 is a key player in the detoxification 
of methylglyoxal, when methylglyoxal spontaneously forms a hemithioacetal with 
glutathione (Thornalley, 2008). Methylglyoxal is a toxic by-product of glycolysis that 
glycates proteins, nucleotides and basic phospholipids (Thornalley, 2008). Besides 
leading to apoptosis, methylglyoxal also influences anxiety behaviour when acting as a 
GABAA receptor agonist (Distler et al., 2012; Thornalley, 2008). GLO1 has been linked 
to diabetic complications, anxiety disorders, schizophrenia, seizure susceptibility, pain, 
cancer and aging (Distler and Palmer, 2012; Thornalley, 2008). 
The third gene, FGD2, is a member of the FGD gene family. FGD genes encode a group 
of guanine nucleotide exchange factors, which, by specifically activating Cdc42, control 
cytoskeleton-dependent membrane rearrangements (Buchsbaum, 2007; Huber et al., 
2008; Rossman et al., 2005; Snyder et al., 2002). 
4.1.2 Examination of differential GLO1 expression in brain tissue 
and cell culture 
In line with the upregulation of GLO1 mRNA detected upon loss of FKBP5 by the 
microarray, the upregulation of GLO1 mRNA was confirmed via quantitative RT-PCR in 
brain lysates from FKBP5-KO and wild type mice used for the microarray (Figure 2A). 
Upregulation of RBM12 could not be verified by quantitative RT-PCR in this sample 
(Figure 2B). Upregulation of GLO1 mRNA was accompanied by a corresponding 
increase in GLO1 protein (Figure 2C). Verification of FGD2 upregulation on mRNA 
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level was not possible due to experimental limitations. With GLO1 being associated with 
psychiatry related phenotypes, the focus was set on the further characterisation of GLO1 
regulation.  
 
Figure 2: Examining the expression of GLO1 and RBM12 in tissue from mice that were mRNA-
profiled on the microarray. Bars show the mean value and error bars represent the standard error of 
the mean. Statistical significances were calculated by a simple t-test and are depicted as follows: * for 
p≤0.05, ** for p≤0.01 and *** for p≤0.001. A GLO1 mRNA upregulation by loss of FKBP5 was 
replicated by qRT-PCR using the RNA preparations analysed on the microarray. GLO1 mRNA 
expression normalised to actin mRNA expression in tissue from FKBP5-KO animals relative to wild 
type tissue was calculated based on the results from three animals of each genotype. B Using the same 
RNA preparations, upregulation of RBM12 mRNA could not be verified by qRT-PCR. RBM12 
mRNA expression normalised to actin mRNA expression in tissue from FKBP5-KO animals relative 
to wild type tissue was calculated. C GLO1 protein upregulation was detected by western analysis in 
brain lysates from the same mice that were analysed on the microarray. A representative western blot 
showing GLO1 and actin expression is attatched. Upregulation of GLO1 protein expression in 
FKBP5-KO tissue normalised to the expression of actin in comparison to wild type tissue was 
calculated from six biological replicates.  
In a next step, the differential expression of GLO1 was verified in a second sample of 
FKBP5-KO mice and in mouse embryonal fibroblasts (MEFs) derived from the 
FKBP5-KO mouse model. Increased expression of GLO1 protein in FKBP5-KO mice 
was confirmed in brain tissue from a second sample of mice by western analysis (Figure 
3A). Consistent with this, an approximately two times upregulated expression of GLO1 
protein was detected in MEFs derived from the FKBP5-KO mice compared to MEFs 
derived from wild type litter mates by western analysis (Figure 3B).  
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For further analysis of the underlying mechanism of the seemingly FKBP5 dependent 
GLO1 expression, efforts were taken to establish a cellular model that would reflect the 
FKBP5 induced regulation of GLO1 expression. Extrapolating from the GLO1 
upregulation in FKBP5-KO mice, ectopic overexpression of FKBP5 in cell culture 
should decrease GLO1 levels. To test this, FKBP5 was overexpressed in HEK-293 cells 
by transient transfection. Surprisingly, increased levels of FKBP51 did not lead to 
downregulation of GLO1 protein as indicated by western analysis (Figure 3C). 
 
Figure 3: Analysing the GLO1 regulation by modulating FKBP5 in cell culture. Bars show the 
mean value and error bars represent the standard error of the mean. Statistical significances were 
calculated by a t-test and are depicted follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. 
Representative western blots are attatched. A Upregulation of GLO1 protein was detected in brain 
tissue from FKBP5-KO mice by western analysis. Upregulation of GLO1 expression in FKBP5-KO 
tissue normalised to the expression of actin in comparison to wild type tissue was calculated from 
twelve biological replicates. B Upregulation of GLO1 protein was detected in MEF cell lysate by 
western analysis. Upregulation of GLO1 expression in FKBP5-KO MEFs normalised to the 
expression of HSC70in comparison to wild type MEFs was calculated from three biological replicates. 
C GLO1 protein is not regulated by ectopic expression of FKBP5 in HEK-293 cells. GLO1 expression 
normalised to actin expression in cells transfected with FLAG-tagged FKBP5 compared to vehicle 
transfected cells was calculated from six biological replicates. 
4.1.3 GLO1 gene duplication in FKBP5 knockout mice 
The discovery of a recurrent spontaneous copy number variation of GLO1 in several 
laboratory mouse inbred lines provided a first hint to a genetic cause for GLO1 
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upregulation (Egan et al., 2007; Shafie et al., 2014). An approximately 475 kb tandem 
duplication on chromosome 17 that includes Glo1 (30,174,390-30,651,226 Mb; mouse 
genome build 36) forms the genetic basis of the duplication of the locus spanning GLO1 
(Williams et al., 2009). This duplication at the GLO1 locus was observed in 23 of 71 
tested inbred mouse strains (Williams et al., 2009). 
As a matter of fact, the genes coding for GLO1 and FKBP51 are both located on mouse 
chromosome 17, separated by only approximately 2 mega bases (Mb). Therefrom, a 
GLO1 copy number variance in the FKBP5 mouse model was considered. 
 
Figure 4: Co-inheritance of a GLO1 gene duplication with the FKBP5-KO allele in FKBP5-KO 
mice. A The genomic arrangement of mouse chromosome 17 with the FKBP5-WT allele compared to 
the FKBP5-KO allele is sketched schematically. Genetic distances on chromosome 17 are marked in 
Mb. B Primer (P1: GLO1-CNV_f and P2: GLO1-CNV_r) complementary to sequences in close 
proximity to the duplication boundary yield a PCR product only in presence of a template providing 
the duplication. C The relative allelic frequency of the GLO1 gene in genomic DNA purified from 
FKBP5-WT, FKBP5-HET and FKBP5-KO animals was quantified in a qPCR with the primer pair 
spanning the duplication boundary. GLO1 gene duplication signal in qPCR was normalised to qPCR 
signal for the NPSR1 genomic DNA on chromosome 7, which served as a reference gene coded on a 
singular locus. Duplication signal in probes from FKBP5-HET animals was set to 1. 
With embryonal stem cell donor mice and back crossing foster mice exhibiting 
differential genetic background FKBP5-KO mice might carry a genetic duplication of 
GLO1, whereas wild type mice might carry a single copy of the GLO1 gene (Figure 4A). 
Moreover, FKBP5 and GLO1 alleles would be co-inherited and the GLO1 copy number 
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variance would be co-selected with the FKBP5 genotype due to their close genetic 
proximity. 
These hypotheses were substantiated by the investigation of the genetic background of 
the FKBP5 mouse model. The FKBP5 deletion was constructed in embryonal stem cells 
derived from 129SvJ mice. Later on, the resulting mice were crossed with C57BL/6 
mice. In contrast to C57BL/6 mice, 129SvJ mice were reported to be carriers of the 
GLO1 gene duplication (Williams et al., 2009). 
Finally, experimental evidence for these hypotheses was provided by the quantification 
of the relative frequency of the duplicated section. Therefore, a primer pair spanning the 
duplication boundary was utilised in a PCR, which exclusively yields a PCR product in 
the presence of a template providing the duplication (Figure 4B). Genomic DNA from 
mice homozygous and heterozygous (FKBP5-HET) for the FKBP5 deletion as well as 
from their wild type litter mates was purified. Using this primer pair in a quantitative 
PCR setup, genomic samples from the three genotypes were probed for the GLO1 
duplication (Williams et al., 2009). Indeed, no GLO1 duplication was detectable in 
FKBP5-WT mice, whereas the PCR signal in FKBP5-KO mice was clearly detectable 
and twice as high as in FKBP5-HET mice (Figure 4C).  
This finding is in line with the hypothesis that FKBP5-KO mice carry two deleted 
FKBP5 alleles, each of them co-segregated with a duplicated GLO1. FKBP5-WT mice, 
hence, carry two functional FKBP5 alleles, each of them co-segregated with a single 
copy of GLO1. FKBP5-HET mice carry one deleted FKBP5 allele co-segregated with a 
duplicated GLO1, and one functional FKBP5 allele co-segregated with a single copy of 
GLO1. 
Therefore, the higher levels of mRNA and protein of GLO1 in FKBP5-KO mice 
compared with wild type litter mates are very likely due to the doubled GLO1 gene dose 
in these mice. 
These results have been published (Kollmannsberger et al., 2013). 
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4.2 Pathway modulation by FKBP51 and psychopharmaca  
As published in two recent publications, we found that AKT and GSK3β as well as 
downstream targets are convergently affected by FKBP51 and the antidepressants PRX 
and LIT (Gassen et al., 2014, 2015). As part of this thesis, potential convergent effects of 
thirteen psychopharmaca and FKBP51 on the kinases GSK3β, AKT and ERK as well as 
their downstream targets were analysed. 
4.2.1 Definition of a cellular system and determination of drug 
treatment 
For this purpose, MEF cells were chosen as cellular model for loss of FKBP51 function. 
Before starting these experiments and additionally in the course of the experiments, the 
existence and purity of the FKBP5 deletion on both DNA and protein level was verified.  
 
Figure 5: Verification of the FKBP5 deletion in MEF cells. A Cell lysate from MEF cells and 
control mouse tissue was probed for the presence of the FKBP5-KO allele as well as the FKBP5-WT 
allele by PCR. A representative agarose gel is shown. B Cell lysate from MEF cells was checked for 
the expression of the FKBP51 protein by western detection. A representative western blot is shown. 
Hence, genotype of cells coding for functional and deleted FKBP5 were determined by PCR 
using primers specific for the wildtype (363 nt product) or mutant (530 nt product) alleles 
(Figure 5A). Tissue from mice heterozygous for the FKBP5 deletion generates two bands 
both for the wildtype and the mutant alleles. The same pattern would be expected for a 
mixed population of MEF cells derived from FKBP5-KO and FKBP5-WT cultures. PCR 
product for FKBP5-WT MEF cells, indeed, exclusively showed a band derived from the 
FKBP5-WT allele, whereas the PCR product for FKBP5-KO MEF cells showed 
exclusively a band derived from the FKBP5-KO allele. 
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Absence of the FKBP51 protein in MEF cells with deleted FKBP5 was verified by 
western detection (Figure 5B). No signal in immune-detection of FKBP51 was obtained 
in FKBP5-KO cells, whereas a distinct signal was found in FKBP5-WT cells. 
   
CTP Citalopram 10 µM 
FLX Fluoxetine 3 µM 
PRX Paroxetine 3 µM 
VTX Vortioxetine 3 µM 
VNF Venlafaxine 10 µM 
AMT Amitriptyline 10 µM 
DXP Doxepin 30 µM 
CLP Clomipramine 10 µM 
TNP Tianeptine 10 µM 
VPA Valproate 5 mM 
LMT Lamotrigine 10 µM 
LIT Lithium 10 mM 
KTM Ketamine 100 µM 
LNC Lanicemine 100 µM 
CHI CHIR-99021 3 µM 
Figure 6: Table of psychopharmaca and additional substances used for pathway modulation 
screen. Depicted are the abbreviation code, the substance name and the concentration used for 
treatment in cell culture, if not described otherwise. 
In addition to PRX and LIT applied in our two recent studies, eleven further 
psychopharmaca of different classes and suspected mode of action well as two additional 
substances were included in this study (Figure 6). CTP and FLX together with PRX 
completed the class of SSRIs. With VTX and VNF, two serotonin and noradrenaline 
modulating drugs were used here. In addition, three drugs with tricyclic structure, AMT, 
DXP and CLP, were included in this study. Furthermore, TNP, an atypical 
antidepressant, was utilised. Moreover, the structurally diverse group of mood stabilisers 
was represented by VPA, LMT and LIT. Moreover, the anaesthetic KTM, which exerts 
antagonistic action on the NMDA receptor, was added to the list of psychopharmaca. 
Finally, two additional substances included LNC, a further drug with antagonistic action 
on the NMDA receptor, and the GSK3β inhibitor CHIR-99021 (CHI). 
Most importantly, cytotoxic effects of high drug concentrations had to be excluded. 
Therefore, two orthogonal toxicity tests in MEF cells were performed with all substances 
for the three incubation times 12 hours, 24 hours, and 48 hours. In the first toxicity test, 
the MTT test, some aspect of general metabolism as a marker of cell viability was 
measured. In the second toxicity test, the LDH test, the egression of a cytosolic enzyme 
into the cell culture medium as a marker of cell membrane integrity was measured. 
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Figure 7: Toxicity of selected SSRIs. Cell viability was analysed after 12 hours, 24 hours and 
48 hours drug treatment and normalised to viability of control treated cells in two assays. Cell 
viability was detected as a measure of general metabolism in the MTT assay and as a measure of cell 
membrane integrity in the LDH assay. Viability rate of 85%, which was defined as toxicity limit, is 
indicated by the dashed line. Cell viability was measured upon treatment with 0.1 µM to 100 µM CTP 
(A), 0.1 µM to 100 µM FLX (B), or 0.1 µM to 100 µM PRX (C). Dots show the mean value and error 
bars represent the standard error of the mean. 
When depressive patients are pharmacologically treated, improvement of symptoms in 
response to treatment with classical antidepressants is found with a delay of weeks. In 
order to mimic a chronic treatment in cell culture, 48 hours incubation time with drugs 
was chosen. Appropriate drug concentrations for the treatment were selected based on 
two criteria: limits of toxicity in the viability assays in MEF cells and drug 
4.2 Pathway modulation by FKBP51 and psychopharmaca 
 
54 
  
concentrations used in recent publications. Toxicity limit in response to drug treatment 
was set to 85% viability rate. If the MTT and the LDH assays indicated different viability 
at a given concentration, viability data from the LDH assay were considered more 
reliable. 
 
Figure 8: Toxicity of selected SSNRIs. Cell viability was analysed after 12 hours, 24 hours and 
48 hours drug treatment and normalised to viability of control treated cells in two assays. Cell 
viability was detected as a measure of general metabolism in the MTT assay and as a measure of cell 
membrane integrity in the LDH assay. Viability rate of 85%, which was defined as toxicity limit, is 
indicated by the dashed line. Cell viability was measured upon treatment with 0.1 µM to 100 µM 
VTX (A) or 0.1 µM to 100 µM VNF (B). Dots show the mean value and error bars represent the 
standard error of the mean. 
CTP did not induce cytotoxic effects up to a maximal concentration of 30 µM (Figure 
7A). Administered at 100 µM, cytotoxic effects became apparent after 48 hours as 
detected both in the MTT and LDH assay. Interestingly, subtoxic concentrations of CTP 
led to enhanced MTT signals, especially after the short exposure time. FLX, the second 
SSRI, was slightly more cytotoxic than CTP (Figure 7B). Already 10 µM FLX induced 
cytotoxic effects after 48 hours as detected both in the MTT and LDH assay. Cytotoxicity 
evoked by treatment with PRX was comparable to cytotoxicity evoked by treatment with 
FLX, with cytotoxic effects starting at concentrations of 10 µM PRX after 48 hours 
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(Figure 7C). Treatment with 3 µM PRX for 48 hours did not induce cytotoxic effects. 
Therefore, 10 µM CTP, 3 µM FLX and 3 µM PRX were used for our following 
experiments if not declared otherwise.  
 
Figure 9: Toxicity of selected TCAs. Cell viability was analysed after 12 hours, 24 hours and 
48 hours drug treatment and normalised to viability of control treated cells in two assays. Cell 
viability was detected as a measure of general metabolism in the MTT assay and as a measure of cell 
membrane integrity in the LDH assay. Viability rate of 85%, which was defined as toxicity limit, is 
indicated by the dashed line. Cell viability was measured upon treatment with 0.1 µM to 100 µM 
AMT (A), 0.1 µM to 100 µM DXP (B), or 0.1 µM to 100 µM CLP (C). Dots show the mean value 
and error bars represent the standard error of the mean. 
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VTX, the most recently approved antidepressant, was starting to induce cytotoxic effects 
at concentrations of 10 µM after 48 hours with slightly more toxic effects measured in 
the MTT than in the LDH assay (Figure 8A). No cytotoxic effects were observed upon 
treatment with VNF in concentrations up to 100 µM in either MTT or LDH assay (Figure 
8B). Therefore, the maximal non-toxic concentration of VTX, i.e. 3 µM, and the subtoxic 
concentration of 10 µM VNF were chosen for further experiments if not declared 
otherwise. 
Cytotoxic effects in response to treatment with 100 µM of the TCA AMT appeared not 
earlier than after 48 hours in either MTT or LDH assay (Figure 9A). No cytotoxic effects, 
but increased MTT signal upon treatment with 30 µM AMT after 12 hours and 24 hours 
were observed with AMT treatment. A similar picture was found for treatment with DXP 
(Figure 9B). Cytotoxic effects were only found with 100 µM DXP after 48 hours 
treatment. Moreover, treatment with 30 µM DXP resulted in a signal induction in the 
MTT assay after 12 hours and even more pronounced after 24 hours. The third TCA, 
CLP, was slightly more toxic (Figure 9C). Cytotoxic effects after 48 hours treatment 
were observed in response to CLP concentrations starting at 30 µM. The typical shoulder 
of signal induction in MTT signal after 12 hours and 24 hours treatment peaked at a 
concentration of 10 µM CLP. Therefore, the concentrations of 10 µM AMT, 30 µM DXP 
and 10 µM CLP were chosen for further experiments if not declared differently. 
 
Figure 10: Toxicity of the atypical antidepressant TNP. Cell viability was analysed after 12 hours, 
24 hours and 48 hours drug treatment and normalised to viability of control treated cells in two assays. 
Cell viability was detected as a measure of general metabolism in the MTT assay and as a measure of 
cell membrane integrity in the LDH assay upon treatment with 0.1 µM to 100 µM TNP. Dots show 
the mean value and error bars represent the standard error of the mean. Viability rate of 85%, which 
was defined as toxicity limit, is indicated by the dashed line. 
No cytotoxic effects were found in response to treatment with the atypical antidepressant 
TNP up to 100 µM in either assay (Figure 10). A signal induction in the MTT assay after 
12 hours and 24 hours, which was found in treatment with CTP and the three TCAs 
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AMT, DXP, and CLP, did not emerge in response to treatment with TNP. Finally, a 
concentration of 10 µM TNP was selected for further experiments. 
 
Figure 11: Toxicity of selected mood stabilisers. Cell viability was analysed after 12 hours, 24 hours 
and 48 hours drug treatment and normalised to viability of control treated cells in two assays. Cell 
viability was detected as a measure of general metabolism in the MTT assay and as a measure of cell 
membrane integrity in the LDH assay. Viability rate of 85%, which was defined as toxicity limit, is 
indicated by the dashed line. Cell viability was measured upon treatment with 0.03 mM to 9 mM VPA 
(A), 0.3 µM to 90 µM LMT (B), or 0.1 mM to 100 mM LIT (C). Dots show the mean value and error 
bars represent the standard error of the mean. 
Different toxicity profiles were observed for the structurally diverse group of mood 
stabilisers (Figure 11). VPA, which was administered up to 9 mM, did not evoke 
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cytotoxicity in the LDH assay and the MTT assay indicated only slightly induced 
cytotoxicity after 48 hours at concentrations starting from 3 mM (Figure 11A). No 
cytotoxicity was observed in response to treatment with the second mood stabiliser LMT 
in either assay at a concentration up to 90 mM (Figure 11B). An induction of signal 
solely in the MTT assay emerged, however, with LMT at all three time points and peaked 
at a concentration of 30 µM. The third mood stabiliser, LIT, started to induce cytotoxic 
effects detected in both assays when administered above 30 µM at all time points. An 
induction of signal solely in the MTT assay was visible after 48 hours incubation peaking 
at a concentration of 3 mM LIT. Hence, 5 µM VPA, 10 µM LMT and 10 mM LIT were 
selected for treatment in further experiments if not declared differently. 
 
Figure 12: Toxicity of the NMDA receptor antagonists KTM. Cell viability was analysed after 
12 hours, 24 hours and 48 hours drug treatment and normalised to viability of control treated cells in 
two assays. Cell viability was detected as a measure of general metabolism in the MTT assay and as a 
measure of cell membrane integrity in the LDH assay. Viability rate of 85%, which was defined as 
toxicity limit, is indicated by the dashed line. Cell viability was measured upon treatment with 0.3 µM 
to 300 µM KTM. Dots show the mean value and error bars represent the standard error of the mean. 
The NMDA receptor antagonist KTM did not induce cytotoxicity over the entire range of 
drug concentrations (Figure 12). A concentration of 100 µM KTM was chosen for 
treatment in further experiments. 
Neither assay indicated cytotoxicity in response to treatment with the NMDA receptor 
antagonist LNC (Figure 13A). Treatment with the GSK3β inhibitor CHI also did not 
evoke cytotoxic effects as indicated by the MTT and the LDH assay up to a concentration 
of 30 µM (Figure 13B). An induction of signal solely in the MTT assay in response to 
treatment with CHI started to emerge at concentrations above 10 µM. Hence, 3 µM CHI 
was chosen for treatment in further experiments. 
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Figure 13: Toxicity of the experimental substances LNC and CHI. Cell viability was analysed after 
12 hours, 24 hours and 48 hours drug treatment and normalised to viability of control treated cells in 
two assays. Cell viability was detected as a measure of general metabolism in the MTT assay and as a 
measure of cell membrane integrity in the LDH assay. Viability rate of 85%, which was defined as 
toxicity limit, is indicated by the dashed line. Cell viability was measured upon treatment with 0.3 nM 
to 300 nM LNC (A) or 0.03 µM to 30 µM CHI (B). Dots show the mean value and error bars 
represent the standard error of the mean. 
4.2.2 Effect of FKBP5 deletion on protein markers previously 
linked to antidepressants 
Next, a potential differential activity-indicating phosphorylation of the kinases GSK3β, 
AKT and ERK2 as well as selected presumptive downstream targets in MEF cells with 
and without the FKBP5 deletion was assessed.  
No difference in the inhibitory phosphorylation of GSK3β at Ser-9 was detected upon 
normalization to the housekeeping protein actin (Figure 14A). Upon normalization to the 
total expression level of GSK3β, however, an increased fraction of phosphorylated 
GSK3β was found in FKBP5-KO cells (Figure 14B). Combining those two findings, 
there was a decrease of the unphosphorylated GSK3β in FKBP5-KO cells, which is the 
active form of the kinase. BCAT is a substrate of GSK3β and becomes phosphorylated 
by GSK3β when pre-phosphorylated at priming sites. Final phosphorylation by GSK3β 
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leads to the destruction of BCAT. Less GSK3β activity in FKBP5-KO cells, however, 
was not reflected by a significant increase in BCAT levels (Figure 14C). The second 
target of GSK3β analysed here was CRMP2, which has been reported to be inactivated 
by GSK3β upon phosphorylation at Thr-514 (Yoshimura et al., 2005). In line with 
lowered GSK3β activity, decreased phosphorylation of CRMP2 in FKBP5-KO cells was 
detected (Figure 14D). 
 
Figure 14: Effect of FKBP5 deletion on selected markers of the GSK3β pathway. The protein 
status of selected markers in MEF cells with and without FKBP5 deletion was analysed by western 
detection. Bars show the mean value and error bars represent the standard error of the mean. Statistical 
significances were calculated by a simple t-test and are depicted as follows: n.s. for p>0.05, * for 
p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Phosphorylation of GSK3β at Ser-9 was quantified and 
normalised to the level of actin from three biological replicates on one western blot. 
B Phosphorylation of GSK3β at Ser-9 was quantified and normalised to the total level of GSK3β from 
three biological replicates on one western blot. C Level of BCAT was quantified and normalised to 
the level of actin from three biological replicates on one western blot. D Phosphorylation of CRMP2 
at Thr-514 was quantified and normalised to the total level of CRMP2 from three biological replicates 
on one western blot. 
A marked increase in phosphorylation of AKT at Ser-473 was found in MEF cells with 
deleted FKBP5 (Figure 15A). This reflects the finding of increased AKT phosphorylation 
due to the absence of FKBP51 mediated formation of the AKT:PHLPP phosphatase 
complex (Pei et al., 2009). Slightly increased levels of the autophagy regulator BECN1 
were found in cells with the FKBP5 deletion (Figure 15B). In those cells, increased 
levels of BECN1 were accompanied by increased lipidation of LC3, both markers of 
increased autophagy (Figure 15C). No difference in phosphorylation of CRMP2 at Ser-
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318 and Ser-321, an assumed target of FKBP51, was detected in cells with deleted 
FKBP5 compared to cells with functional FKBP5 (Figure 15D). 
 
Figure 15: Effect of FKBP5 deletion on selected markers of the AKT and autophagy pathway.  
The protein status of selected markers in MEF cells with and without FKBP5 deletion was analysed 
by western detection. Bars show the mean value and error bars represent the standard error of the 
mean. Statistical significances were calculated by a simple t-test and are depicted as follows: n.s. for 
p>0.05, * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Phosphorylation of AKT at Ser-473 was 
quantified and normalised to the total level of AKT from three biological replicates on one western 
blot. B The level of BECN1 was quantified and normalised to the level of actin from three biological 
replicates on one western blot. C Conversion of LC3-I to LC3-II was calculated as the ratio of 
quantified LC3-II to LC3-I from three biological replicates on one western blot. D Phosphorylation of 
FOXO3α at Ser-318 and Ser-321 was quantified and normalised to the total level of FOXO3α from 
three biological replicates on one western blot. 
With both FKBP51 and ERK being responsive to stress on the one hand and ERK being 
regulated by the HSP90 complex on the other hand, a potential physical interaction of 
FKBP51 with ERK was tested initially (Dou et al., 2005). FLAG-tagged FKBP51 and 
HA-tagged ERK1 was expressed in HEK-293 cells to assess their interaction by co-
immunoprecipitation. Indeed, ERK1 displayed binding to FKBP51 and FKBP51 
displayed binding to ERK1, respectively (Figure 16A). 
Based on the interaction of FKBP51 with ERK1, next a potential differential 
phosphorylation of ERK in the presence or absence of FKBP51 was assessed. Indeed, 
increased phosphorylation of both ERK1 and ERK2 at Thr-202 and Tyr-204 was 
detected in MEF cells with deleted FKBP5, with similarly increased phosphorylation in 
both ERK isoforms (Figure 16B). 
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Figure 16: Interaction of FKBP51 with ERK and effect of FKBP5 deletion on ERK 
phosphorylation. A FKBP5 interacts with ERK. HEK-293 cells were transfected either with 
ERK1(HA) in combination with vector control or FKBP51(FLAG) expressing plasmids (lanes 1 and 
2) or with FKBP51(FLAG) in combination with vector control or ERK1(HA) expressing plasmids 
(lanes 3 and 4). Cells were lysed 72 h after transfection. Proteins from lysates were 
immunoprecipitated with FLAG antibody (lanes 1 and 2) or HA antibody (lanes 3 and 4) and analysed 
by western detection. B ERK phosphorylation in MEF cells with and without FKBP5 deletion was 
analysed by western detection. Phosphorylation of ERK1 and ERK2 at Thr-202 and Tyr-204 was 
quantified and normalised to the total level of ERK1 and ERK2, respectively, from three biological 
replicates on one western blot. Bars show the mean value and error bars represent the standard error of 
the mean. Statistical significances were calculated by a simple t-test and are depicted as follows: n.s. 
for p>0.05, * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. 
4.2.3 Responsiveness of selected protein markers to 
psychopharmaca treatment 
FKBP5 was originally selected as a candidate gene for genetic analyses in depression and 
antidepressant responsiveness (Binder et al., 2004). Focusing on the protein level, the 
aim of this work was to analyse the responsiveness of pathways relevant to psychiatric 
diseases. MEF cells with and without a functional FKBP5 were treated with 
psychopharmaca and utilised as a cellular model for FKBP5-dependent effects. 
GSK3β phosphorylation 
As a first marker, the responsiveness in activity of GSK3β to treatment with 
psychopharmaca and experimental substances was analysed. Several psychopharmaca 
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increased the phosphorylation of GSK3β at Ser-9 normalised to the expression of the 
housekeeping protein actin and therefore inhibited GSK3β activity (Figure 17A).  
 
Figure 17: Responsiveness of GSK3β phosphorylation to treatment with psychopharmaca.  
GSK3β phosphorylation at Ser-9 in MEF cells with and without FKBP5 deletion was analysed by 
western detection after treatment with the indicated drugs for 48 hours. GSK3β phosphorylation was 
quantified and normalised to the level of actin or GSK3β as indicated from three biological replicates. 
Responsiveness to treatment in MEF cells with and without the FKBP5 deletion was calculated as 
ratio of values upon treatment divided by value upon control treatment in the respective cell line, 
which was thereby set to 1 and is indicated by the dashed line.  
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Bars show the mean value and error bars represent the standard error of the mean. Statistical 
significances were calculated by a two-way analysis of variance combined with a Bonferroni post-hoc 
test and are depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Responsiveness 
to treatment with psychopharmaca of GSK3β phosphorylation normalised to actin was assessed. 
B Responsiveness to treatment with psychopharmaca of GSK3β phosphorylation normalised to 
GSK3β was assessed. C Responsiveness to treatment with experimental substances of GSK3β 
phosphorylation normalised to actin was assessed. D Responsiveness to treatment with experimental 
substances of GSK3β phosphorylation normalised to GSK3β was assessed. E Exemplary western 
signals for vehicle, AMT, CLP and VPA treatment of cells with and without the FKBP5 deletion are 
depicted. 
CTP, LMT and LIT significantly increased GSK3β phosphorylation in MEF cells with 
functional FKBP5, whereas CLP and VPA significantly increased GSK3β 
phosphorylation in MEF cells with deleted FKBP5. Moreover, the GSK3β inhibitor CHI 
significantly increased GSK3β phosphorylation exclusively in MEF cells with functional 
FKBP5 (Figure 17C). No significant decrease in GSK3β phosphorylation was observed 
in response to treatment with any of the psychopharmaca. Significant FKBP5 dependent 
effects with exclusive or at least higher responsiveness in MEF cells with functional 
FKBP5 were evoked by treatment with drugs from all subclasses including CTP, PRX, 
VNF, DXP, TNP, LMT, LIT and CHI. Increased or exclusive responsiveness in MEF 
cells with deleted FKBP5 was observed for treatment with AMT, CLP and VPA. 
Interestingly, the increase in phosphorylated GSK3β in response to treatment generally 
appeared slightly attenuated when normalising to total GSK3β level (Figure 17B and 
Figure 17D). This is due to the observation that treatment with psychopharmaca tended 
to increase the level of total GSK3β compared to actin. When normalised to total GSK3β 
levels, significant decrease in GSK3β phosphorylation was detected in MEF cells with 
functional FKBP5 treated with PRX, VTX and CLP as well as in MEF cells with deleted 
FKBP5 treated with FLX and PRX. Increased phosphorylation was detected in MEF cells 
with functional FKBP5 upon treatment with LMT and LNC.  
Significant FKBP5 dependency with exclusive or at least higher responsiveness in MEF 
cells with functional FKBP5 was observed in response to treatment with drugs from all 
subclasses including CTP, VNF, DXP, TNP, LMT, LNC, CHI. Increased or exclusive 
responsiveness in MEF cells with deleted FKBP5 was noted for treatment with VTX, 
AMT and CLP. 
BCAT 
GSK-3β plays an important role in regulating BCAT levels. Inhibition of GSK-3β has 
been shown to result in BCAT accumulation, due to a decrease in the rate of BCAT 
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protein degradation (Nishimura et al., 1999). While significant accumulation of BCAT to 
treatment was only observed for PRX in MEF cells with deleted FKBP5, increased 
degradation of BCAT was detected in MEF cells with functional FKBP5 treated with 
CLP, VPA and LMT as well as in MEF cells with deleted FKBP5 treated with LMT and 
CHI (Figure 18A, Figure 18B). Treatment with PRX actually increased BCAT levels. 
 
Figure 18: Responsiveness of BCAT stability to treatment with psychopharmaca. BCAT 
expression in MEF cells with and without FKBP5 deletion was analysed by western detection after 
treatment with the indicated drugs for 48 hours. Level of BCAT was quantified and normalised to the 
level of actin from three biological replicates. Responsiveness to treatment in MEF cells with and 
without the FKBP5 deletion was calculated as ratio of values upon treatment divided by value upon 
control treatment in the respective cell line, which was thereby set to 1 and is indicated by the dashed 
line. Bars show the mean value and error bars represent the standard error of the mean. Statistical 
significances were calculated by a two-way analysis of variance combined with a Bonferroni post-hoc 
test and are depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Responsiveness 
of BCAT expression level to treatment with psychopharmaca was assessed. B Responsiveness of 
BCAT expression level to treatment with experimental substances was assessed. C Exemplary 
western signals for vehicle, AMT, CLP and VPA treatment of cells with and without the FKBP5 
deletion are depicted. 
 Significant FKBP5 dependent effects with exclusive or at least higher responsiveness in 
MEF cells with functional FKBP5 were evoked in response to treatment with CTP, LIT 
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and CHI. Increased or exclusive responsiveness in MEF cells with deleted FKBP5 was 
observed in response to treatment with PRX, AMT and CLP. 
CRMP2 phosphorylation 
 
Figure 19: Responsiveness of CRMP2 phosphorylation to treatment with psychopharmaca.  
CRMP2 phosphorylation at Thr-514 in MEF cells with and without FKBP5 deletion was analysed by 
western detection after treatment with the indicated drugs for 48 hours. Level of CRMP2 
phosphorylation was quantified and normalised to the total level of CRMP2 from three biological 
replicates. Responsiveness to treatment in MEF cells with and without the FKBP5 deletion was 
calculated as ratio of values upon treatment divided by value upon control treatment in the respective 
cell line, which was thereby set to 1 and is indicated by the dashed line. Bars show the mean value and 
error bars represent the standard error of the mean. Statistical significances were calculated by a two-
way analysis of variance combined with a Bonferroni post-hoc test and are depicted as follows: * for 
p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Responsiveness of CRMP2 phosphorylation to 
treatment with psychopharmaca was assessed. B Responsiveness of CRMP2 phosphorylation to 
treatment with experimental substances was assessed. C Exemplary western signals for vehicle, AMT, 
CLP and VPA treatment of cells with and without the FKBP5 deletion are depicted. 
A further target of GSK3β and a protein associated with psychiatric diseases is CRMP2, 
which is phosphorylated by GSK3β at Thr-509 and Thr-514 Thus, the responsiveness of 
CRMP2 phosphorylation at Thr-509 and Thr-514 to treatment with psychopharmaca and 
experimental drugs was analysed (Figure 19A and Figure 19B). Both increase and 
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decrease in CRMP2 phosphorylation was observed in response to treatment. 
Interestingly, a distinct pattern in responsiveness to treatment was observed with regard 
to class subgroups. Decreased phosphorylation was observed in response to treatment 
with the three mood stabiliser VPA, LMT and LIT as well as the GSK3β inhibitor CHI in 
cells with functional FKBP5. This is, at least for three out of four drugs, in line with 
inhibited GSK3β activity, which was observed in response to treatment with CTP, LMT, 
LIT and CHI. In cells with deleted FKBP5, however, decreased phosphorylation was 
observed in response to treatment with the TCAs DXP and CLP and the mood stabiliser 
VPA and LIT. On the other hand, a significant increase in CRMP2 phosphorylation was 
found in response to treatment with AMT in cells with functional FKBP5 as well as in 
response to treatment with PRX and TNP in cells with deleted FKBP5. 
Differential effects with regard to the presence or absence of functional FKBP5 were 
observed for all three TCAs AMT, DXP and CLP as well as the NMDA receptor 
antagonist LNC with lower CRMP2 phosphorylation in cells with deleted FKBP5. 
Opposite effects with lower CRMP2 phosphorylation in cells with functional FKBP5 
were detected in response to treatment with the SSRIs FLX and PRX, the SSNRI VTX, 
the atypical antidepressant TNP, the NMDA receptor antagonist KTM and the GSK3β 
inhibitor CHI. 
AKT phosphorylation 
Next, the responsiveness of AKT phosphorylation at Ser-473 to treatment with 
psychopharmaca (Figure 20A) and experimental drugs (Figure 20B) in cells with either 
functional or deleted FKBP5 was analysed. Treatment with several drugs, including CTP, 
PRX AMT and LMT, significantly increased the phosphorylation of AKT in cells with 
functional FKBP5. In cells with deleted FKBP5 a significant increase in AKT 
phosphorylation was observed in response to treatment with the TCAs AMT and CLP.  
Differential effects of loss of FKBP51 function were observed for all three SSRIs CTP, 
FLX and PRX, as well as for two mood stabiliser LMT and LIT with higher AKT 
phosphorylation in cells with functional FKBP5. Opposite effects with lower AKT 
phosphorylation in cells with functional FKBP5 were detected in response to treatment 
with CLP. 
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Figure 20: Responsiveness of AKT phosphorylation to treatment with psychopharmaca. AKT 
phosphorylation at Ser-473 in MEF cells with and without FKBP5 deletion was analysed by western 
detection after treatment with the indicated drugs for 48 hours. Level of AKT phosphorylation was 
quantified and normalised to the total level of AKT from three biological replicates. Responsiveness 
to treatment in MEF cells with and without the FKBP5 deletion was calculated as ratio of values upon 
treatment divided by value upon control treatment in the respective cell line, which was thereby set to 
1 and is indicated by the dashed line. Bars show the mean value and error bars represent the standard 
error of the mean. Statistical significances were calculated by a two-way analysis of variance 
combined with a Bonferroni post-hoc test and are depicted as follows* for p≤0.05, ** for p≤0.01 and 
*** for p≤0.001. A Responsiveness of AKT phosphorylation to treatment with psychopharmaca was 
assessed. B Responsiveness of AKT phosphorylation to treatment with experimental substances was 
assessed. C Exemplary western signals for vehicle, AMT, CLP and VPA treatment of cells with and 
without the FKBP5 deletion are depicted. 
BECN1 
In order to unravel a potential effect of psychopharmaca on the initiation of autophagy, 
the expression levels of BECN1, a regulator of the VPS34 complex in response to 
treatment with psychopharmaca and experimental drugs were analysed (Figure 21A and 
Figure 21B). A significant accumulation of BECN1 was detected in response to treatment 
with CLP in cells with functional FKBP5 as well as in response to treatment with CTP 
and LMT in cells with deleted FKBP5. A significant decrease in the expression level of 
BECN1 in response to treatment was not observed.  
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Figure 21: Responsiveness of BECN1 stability to treatment with psychopharmaca. BECN1 
expression in MEF cells with and without FKBP5 deletion was analysed by western detection after 
treatment with the indicated drugs for 48 hours. Level of BECN1 was quantified and normalised to the 
level of actin from three biological replicates. Responsiveness to treatment in MEF cells with and 
without the FKBP5 deletion was calculated as ratio of values upon treatment divided by value upon 
control treatment in the respective cell line, which was thereby set to 1 and is indicated by the dashed 
line. Bars show the mean value and error bars represent the standard error of the mean. Statistical 
significances were calculated by a two-way analysis of variance combined with a Bonferroni post-hoc 
test and are depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Responsiveness 
of BECN1 expression level to treatment with psychopharmaca was assessed. B Responsiveness of 
BECN1 expression level to treatment with experimental substances was assessed. C Exemplary 
western signals for vehicle, AMT, CLP and VPA treatment of cells with and without the FKBP5 
deletion are depicted. 
Differential effects of loss of FKBP51 function were observed for all three TCAs AMT, 
DXP, and CLP as well as VPA and LNC with higher BECN1 levels in cells with 
functional FKBP5. Higher BECN1 levels in cells with deleted FKBP5 were detected in 
response to treatment with the two SSRIs CTP and PRX as well as the two mood 
stabiliser LMT and LIT. 
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LC3 conversion 
Next, it was analysed if psychopharmaca increased autophagy indicated by LC3-II to 
LC3-I conversion (Figure 22A and Figure 22B). Increased conversion of LC3 in cells 
with functional FKBP5 was observed in response to treatment with the SSRIs FLX and 
PRX, the SNRI VTX and the SSRIs DXP and CLP. In cells with deleted FKBP5, 
increased conversion of LC3 was measured in response to treatment with FLX, VTX and 
all three TCAs AMT, DXP, and CLP. 
 
Figure 22: Responsiveness of LC3 conversion to treatment with psychopharmaca. LC3 
conversion in MEF cells with and without FKBP5 deletion was analysed by western detection after 
treatment with the indicated drugs for 48 hours. Level of LC3-II was quantified and normalised to the 
level of LC3-I from three biological replicates. Responsiveness to treatment in MEF cells with and 
without the FKBP5 deletion was calculated as ratio of values upon treatment divided by value upon 
control treatment in the respective cell line, which was thereby set to 1 and is indicated by the dashed 
line. Bars show the mean value and error bars represent the standard error of the mean. Statistical 
significances were calculated by a two-way analysis of variance combined with a Bonferroni post-hoc 
test and are depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Responsiveness 
of LC3 conversion to treatment with psychopharmaca was assessed. B Responsiveness of LC3 
conversion to treatment with experimental substances was assessed. C Exemplary western signals for 
vehicle, AMT, CLP and VPA treatment of cells with and without the FKBP5 deletion are depicted. 
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Differential effects of FKBP5 deletion were observed in response to treatment with PRX, 
LMT and CHI with higher LC3 conversion in cells with functional FKBP5. On the other 
hand, higher LC3 conversion in cells with deleted FKBP5 was detected in response to 
treatment with all three TCAs AMT, DXP, and CLP. Interestingly, decreased LC3-II to 
LC3-I conversion was exclusively observed in response to treatment with the mood 
stabiliser VPA in cells with either functional or deleted FKBP5, which was, however, not 
significant.  
FOXO3α phosphorylation 
 
Figure 23: Responsiveness of FoxO3α phosphorylation to treatment with psychopharmaca.  
FOXO3α phosphorylation at Ser-318 and Ser-321 in MEF cells with and without FKBP5 deletion was 
analysed by western detection after treatment with the indicated drugs for 48 hours. Level of FOXO3α 
phosphorylation was quantified and normalised to the total level of FOXO3α from three biological 
replicates. Responsiveness to treatment in MEF cells with and without the FKBP5 deletion was 
calculated as ratio of values upon treatment divided by value upon control treatment in the respective 
cell line, which was thereby set to 1 and is indicated by the dashed line. Bars show the mean value and 
error bars represent the standard error of the mean. Statistical significances were calculated by a two-
way analysis of variance combined with a Bonferroni post-hoc test and are depicted as follows: * for 
p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Responsiveness of FOXO3α phosphorylation to 
treatment with psychopharmaca was assessed. B Responsiveness of FOXO3α phosphorylation to 
treatment with experimental substances was assessed. C Exemplary western signals for vehicle, AMT, 
CLP and VPA treatment of cells with and without the FKBP5 deletion are depicted. 
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A potential link between AKT and regulation of autophagy may be provided by the 
transcription factor FOXO3α, whose activity is, amongst others, regulated by AKT via 
phosphorylation at Ser-318 and Ser-321 (Rena et al., 2002). Therefore, the 
responsiveness of FOXO3α phosphorylation to treatment with psychopharmaca (Figure 
23A) and experimental drugs (Figure 23B) was analysed in cells with functional or 
deleted FKBP5. Indeed, significantly increased FOXO3α phosphorylation was detected 
in response to treatment with FLX and VTX in cells with functional FKBP5. In cells with 
deleted FKBP5, increased FOXO3α phosphorylation was detected in response to 
treatment with AMT. Differential effects in regard to FKBP5 were observed in response 
to treatment with FLX, VTX, VPA and LNC with higher FOXO3α phosphorylation in 
cells with functional FKBP5. Increased FOXO3α phosphorylation in cells with deleted 
FKBP5 was detected in response to treatment with the two TCAs AMT and CLP. 
ERK2 phosphorylation 
It was recently reported that antidepressant treatment equally affects the activation of one 
of the two isoforms, ERK1 and ERK2, with respect to the other (Di Benedetto et al., 
2013). In respect to a similar effect in ERK1 and ERK2 phosphorylation in MEF cells 
with deleted FKBP5, the analysis of ERK phosphorylation in response to treatment with 
psychopharmaca and experimental drugs  was focused on ERK2, which was higher 
abundant and thus could be more reliably determined (Figure 24A and Figure 24B). In 
cells with functional FKBP5, treatment with CTP, VNF, TNP, VPA, LMT, KTM and 
CHI significantly increased phosphorylation of ERK2. ERK2 phosphorylation in cells 
with deleted FKBP5, however, did not significantly respond to treatment. Significant 
differential responsiveness in cells with functional FKBP5 compared to cells with deleted 
FKBP5 was observed in the treatment with CTP, VNF, TNP, KTM and CHI. Markedly, 
treatment with any of the three mood stabilisers VPA, LMT and LIT provoked a 
significantly difference in responsiveness in cells with functional FKBP5 compared to 
cells with deleted FKBP5. 
Strikingly, a general FKBP5 dependent responsiveness in the phosphorylation of ERK2 
to treatment with psychopharmaca was observed. A marked increase in ERK2 
phosphorylation in response to average drug treatment in cells with functional FKBP5 
was detected, which was not reflected in cells with deleted FKBP5. 
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Figure 24: Responsiveness of ERK2 phosphorylation to treatment with psychopharmaca.  ERK2 
phosphorylation at Thr-202 and Tyr-204 in MEF cells with and without FKBP5 deletion was analysed 
by western detection after treatment with the indicated drugs for 48 hours. Level of ERK2 
phosphorylation was quantified and normalised to the total level of ERK2 from three biological 
replicates. Responsiveness to treatment in MEF cells with and without the FKBP5 deletion was 
calculated as ratio of values upon treatment divided by value upon control treatment in the respective 
cell line, which was thereby set to 1 and is indicated by the dashed line. Bars show the mean value and 
error bars represent the standard error of the mean. Statistical significances were calculated by a two-
way analysis of variance combined with a Bonferroni post-hoc test and are depicted as follows: * for 
p≤0.05, ** for p≤0.01 and *** for p≤0.001. A Responsiveness of ERK2 phosphorylation to treatment 
with psychopharmaca was assessed. B Responsiveness of ERK2 phosphorylation to treatment with 
experimental substances was assessed. C Exemplary western signals for vehicle, AMT, CLP and VPA 
treatment of cells with and without the FKBP5 deletion are depicted. 
4.2.4 Modulation of transcription factor activity by 
psychopharmaca treatment 
In addition to the analysis of expression and phosphorylation of proteins, the 
transcriptional activity of proteins, which are under control of pathways relevant for 
psychiatric diseases, was assesed. 
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TCF/LEF 
 
Figure 25: Regulation of TCF/LEF activity by psychopharmaca and FKBP5. Transcriptional 
activity of TCF/LEF was analysed in a dual luciferase based setup in MEF cells with and without the 
FKBP5 deletion. MEF cells were transfected with plasmids coding for firefly luciferase under control 
of a TCF/LEF dependent promoter, gaussia luciferase under control of a CMV promoter as well as 
FKBP51(FLAG) or control vector. Cells were treated 24 hours after transfection with the indicated 
drugs or vehicle for 48 hours. After cell lysis, light emission upon addition of firefly and gaussia 
substrate, subsequently, was measured. Firefly signal was normalised to gaussia signal. Bars show the 
mean value and error bars represent the standard error of the mean. Statistical significances were 
calculated by a two-way analysis of variance combined with a Bonferroni post-hoc test and are 
depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. A TCF/LEF activity was 
measured for each of the three FKBP5 conditions upon vehicle treatment and calculated as relative 
signal compared to signal from MEF cells without the FKBP5 deletion. B Responsiveness in 
TCF/LEF activity was measured for each of the three FKBP5 conditions upon treatment with 
experimental drugs and calculated as relative signal compared to signal from the respective FKBP5 
condition in vehicle treated cells, which was thereby set to 1 and is indicated by the dashed line. 
C Responsiveness in TCF/LEF activity was measured for each of the three FKBP5 conditions upon 
treatment with psychopharmaca and calculated as relative signal compared to signal from the 
respective FKBP5 condition in vehicle treated cells, which was thereby set to 1 and is indicated by the 
dashed line. 
T-cell factor/lymphoid enhancing factor (TCF/LEF) transcription factors present a group 
of transcription factors, which are controlled by GSK3β and BCAT in the Wnt signalling 
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pathway. In order to get a further readout for the ability of GSK3β to suppress 
downstream targets in response to FKBP5 deletion and treatment with psychopharmaca, 
the transcriptional activity of TCF/LEF was analysed in a dual luciferase based reporter 
construct in MEF cells with functional, deleted, or ectopic FKBP5.  
Indeed, a significantly reduced transcriptional activity was detected in cells with deleted 
FKBP5 compared to cells with functional FKBP5 (Figure 25A). This reduction in 
transcriptional activity, however, could not be reversed by ectopic expression of FKBP5 
in cells with deleted FKBP5 (Figure 25A).  
In order to unravel the responsiveness of TCF/LEF activity to treatment, MEF cells with 
functional, deleted, or ectopic FKBP5 were treated with the experimental substances 
LNC, CHI or the HDAC inhibitor Trichostatin A (TSA) (Figure 25B). Treatment with 
CHI significantly increased the TCF/LEF activity in cells with functional FKBP5, but not 
in cells with deleted, or ectopic FKBP5. Treatment with TSA, however, significantly 
increased TCF/LEF activity in cells with deleted FKBP5 irrespectively of ectopic FKBP5 
expression. In cells with functional FKBP5 no increase in TCF/LEF activity was 
observed in response to treatment with TSA. 
No significant change in TCF/LEF activity was observed in response to treatment with 
most psychopharmaca (Figure 25C). Increase in TCF/LFE activity was solely measured 
in response to treatment with the mood stabilisers VPA and LIT. A non-significant 
increase in response to VPA treatment was detected in cells with functional FKBP5. A 
significant and even more pronounced increase in response to VPA treatment was 
detected in cells with deleted FKBP5 irrespectively of ectopic FKBP5 expression. 
Treatment with LIT non-significantly increased TCF/LEF activity in cells with either 
functional, deleted, or ectopic FKBP5. 
Consecutively, begin of dose dependent treatment effects on TCF/LEF activity was 
analysed. Therefore, two concentrations of selected drugs from the groups of SSRIs, 
SSNRIs, TCAs and mood stabilisers were tested on their potential to modulate TCF/LEF 
activity in MEF cells with functional, deleted, or ectopic FKBP5. 
In addition to 3 µM PRX, which was the concentration used in the preceding 
experiments, cells were treated with 10 µM PRX (Figure 26A). Treatment with 3 µM, 
but not 10 µM PRX significantly inhibited TCF/LEF activity in cells with functional 
FKBP5. In cells with deleted FKBP5, treatment with both 3 µM and 10 µM PRX 
inhibited TCF/LEF activity irrespectively of ectopic FKBP5 expression.  
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Figure 26: Dose dependent effects of selected psychopharmaca on TCF/LEF activity. 
Transcriptional activity of TCF/LEF was analysed in a dual luciferase based setup in MEF cells with 
and without the FKBP5 deletion. MEF cells were transfected with plasmids coding for firefly 
luciferase under control of a TCF/LEF dependent promoter, gaussia luciferase under control of a 
CMV promoter as well as FKBP51(FLAG) or control vector. Cells were treated 24 hours after 
transfection with the indicated drugs or vehicle for 48 hours. After cell lysis, light emission upon 
addition of firefly and gaussia substrate, subsequently, was measured. Firefly signal was normalised to 
gaussia signal. Responsiveness in TCF/LEF activity was measured for each of the three FKBP5 
conditions upon treatment and calculated as relative signal compared to signal from the respective 
FKBP5 condition in vehicle treated cells. Bars show the mean value and error bars represent the 
standard error of the mean. Statistical significances were calculated by a two-way analysis of variance 
combined with a Bonferroni post-hoc test. Statistical significant differences compared to vehicle 
treatment are depicted with * and pairwise statistical differences with # as follows: */# for p≤0.05, **/## 
for p≤0.01 and ***/### for p≤0.001.  
A dose dependent effect in response to treatment with the SNRI VTX was observed for 
TCF/LEF activity (Figure 26B). Treatment with 3 µM, but not 1 µM, VTX inhibited 
TCF/LEF activity in cells with functional FKBP5. In cells with deleted FKBP5, 
treatment with neither 1 µM nor 3 µM VTX modulated TCF/LEF irrespectively of 
ectopic FKBP5 expression. 
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Inhibition of TCF/LEF activity was observed in response to treatment with the TCA CLP 
with no significant difference between the two drug concentrations (Figure 26C). 
Treatment with 3 µM and 10 µM CLP dose dependently inhibited TCF/LEF activity in 
cells with functional FKBP5 as well as in cells with deleted FKBP5.  
Treatment with 5 µM and 15 µM VPA generally increased TCF/LEF activity (Figure 
26D). The increase in TCF/LEF activity in response to VPA treatment in cells with 
functional FKB5 was, however, not significant. Treatment with both concentrations of 
VPA markedly increased TCF/LEF activity in cells with deleted FKBP5 irrespectively of 
ectopic FKBP5 expression. There was a significant difference in responsiveness to VPA 
treatment between cells with deleted FKBP5 and functional FKBP5. This difference, 
however, was lost as a result of ectopic FKBP5 expression in cells with deleted FKBP5.  
Treatment with LIT dose-dependently increased TCF/LEF activity (Figure 26E). A 
significant increase in TCF/LEF activity was observed in response to treatment with 
30 mM, but not 10 mM, LIT. This effect, however, was not dependent on the FKBP5 
status. 
FOXO3α 
The activity of a further transcription factor, FOXO3α, is controlled via its 
phosphorylation status, amongst others by AKT dependent phosphorylation at Ser-318 
and Ser-321. As a further readout, the activity of FOXO3a was analysed in a dual 
luciferase based reporter construct in MEF cells with functional, deleted, or ectopic 
FKBP5. 
No difference in FOXO3α activity was measured in cells with deleted or ectopic FKBP5 
compared to cells with functional FKBP5 (Figure 27B). In order to unravel the 
responsiveness of FOXO3α activity to treatment, MEF cells with functional, deleted, or 
ectopic FKBP5 were treated with the experimental substances LNC, CHI or the AKT 
inhibitor triciribine (TCB) (Figure 27B) (Evangelisti et al., 2011). Treatment with LNC 
or CHI did not modulate FOXO3α activity. In line with inhibitory kinase activity of AKT 
on FOXO3α, treatment with TCB significantly increased FOXO3α activity in cells with 
functional FKBP5. This effect was even more pronounced in cells with deleted FKBP5. 
No marked reduction in FOXO3α activity in response to TCB treatment was observed by 
ectopic expression of FKBP5 in cells with deleted FKBP5. 
No significant change in FOXO3α activity was observed in response to treatment with 
most psychopharmaca (Figure 27C). Increase in TCF/LFE activity was solely measured 
in response to treatment with the mood stabiliser VPA. A significant increase in response 
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to VPA treatment was detected in cells with functional FKBP5. A significantly more 
pronounced increase in response to VPA treatment was detected in cells with deleted 
FKBP5 irrespectively of ectopic FKBP5 expression. 
 
Figure 27: Regulation of the FoxO3α activity by psychopharmaca and FKBP5. Transcriptional 
activity of FOXO3α was analysed in a dual luciferase based setup in MEF cells with and without the 
FKBP5 deletion. MEF cells were transfected with plasmids coding for firefly luciferase under control 
of a FOXO3α dependent promoter, gaussia luciferase under control of a CMV promoter as well as 
FKBP51(FLAG) or control vector. Cells were treated 24 hours after transfection with the indicated 
drugs or vehicle for 48 hours. After cell lysis, light emission upon addition of firefly and gaussia 
substrate, subsequently, was measured. Firefly signal was normalised to gaussia signal. Bars show the 
mean value and error bars represent the standard error of the mean. Statistical significances were 
calculated by a two-way analysis of variance combined with a Bonferroni post-hoc test and are 
depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001. A FOXO3α activity was 
measured for each of the three FKBP5 conditions upon vehicle treatment and calculated as relative 
signal compared to signal from MEF cells without the FKBP5 deletion. B Responsiveness in FOXO3α 
activity was measured for each of the three FKBP5 conditions upon treatment with experimental drugs 
and calculated as relative signal compared to signal from the respective FKBP5 condition in vehicle 
treated cells, which was thereby set to 1 and is indicated by the dashed line. C Responsiveness in 
FOXO3α activity was measured for each of the three FKBP5 conditions upon treatment with 
psychopharmaca and calculated as relative signal compared to signal from the respective FKBP5 
condition in vehicle treated cells, which was thereby set to 1 and is indicated by the dashed line. 
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Consecutively, begin of dose dependent treatment effects on TCF/LEF activity was 
analysed. In order to answer this question, two concentrations of selected drugs from the 
groups of SSRIs, SSNRIs, TCAs and mood stabilisers were tested on their potential to 
modulate FOXO3α activity in MEF cells with functional, deleted, or ectopic FKBP5. 
 
Figure 28: Dose dependent effects of selected psychopharmaca on FOXO3α activity. 
Transcriptional activity of FOXO3α was analysed in a dual luciferase based setup in MEF cells with 
and without the FKBP5 deletion. MEF cells were transfected with plasmids coding for firefly 
luciferase under control of a FOXO3α dependent promoter, gaussia luciferase under control of a CMV 
promoter as well as FKBP51(FLAG) or control vector. Cells were treated 24 hours after transfection 
with the indicated drugs or vehicle for 48 hours. After cell lysis, light emission upon addition of 
firefly and gaussia substrate, subsequently, was measured. Firefly signal was normalised to gaussia 
signal. Responsiveness in FOXO3α activity was measured for each of the three FKBP5 conditions 
upon treatment and calculated as relative signal compared to signal from the respective FKBP5 
condition in vehicle treated cells. Bars show the mean value and error bars represent the standard error 
of the mean. Statistical significances were calculated by a two-way analysis of variance combined 
with a Bonferroni post-hoc test. Statistical significant differences compared to vehicle treatment are 
depicted with * and pairwise statistical differences with # as follows: */# for p≤0.05, **/## for p≤0.01 
and ***/### for p≤0.001.  
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Neither 3 µM nor 10 µM PRX modulated FOXO3α activity in MEF cells with 
functional, deleted, or ectopic FKBP5 (Figure 28A). Likewise, no modulation of 
FOXO3α activity in MEF cells with functional, deleted, or ectopic FKBP5 was observed 
in response to treatment with 1 µM or 3 µM VTX (Figure 28B).  
Inhibition of FOXO3α activity was measured in response to treatment with CLP (Figure 
28C). Treatment with 10 µM but not 3 µM CLP significantly inhibited FOXO3α activity 
in cells with functional FKBP5. Inhibition was also observed in cells with deleted 
FKBP5 in response to treatment with either 3 µM or 10 µM CLP. This inhibitory effect 
in response to treatment with CLP in cells with deleted FKBP5 was lost when FKBP5 
was expressed ectopically.   
A pronounced FOXO3α activating effect was observed in response to treatment with 
5 mM and 15 mM VPA (Figure 28D). The increase in FOXO3α activity in response to 
VPA treatment in cells with functional FKB5 was, however, not significant. In cells with 
deleted FKBP5, treatment with both concentrations of VPA markedly increased 
FOXO3α activity irrespectively of ectopic FKBP5 expression. There was a significant 
difference in responsiveness to VPA treatment between cells with deleted FKBP5 and 
functional FKBP5.  
Treatment with 10 mM and 30 mM LIT dose dependently increased FOXO3α activity 
(Figure 28E). In cells with functional FKBP5, treatment with both 10 mM and 30 mM 
LIT significantly increased FOXO3α activity. In cells with deleted FKBP5, however, no 
increase in FOXO3α activity was observed in response to treatment with 10 mM LIT. 
Only at a concentration of 30 mM LIT a significant increase in FOXO3α activity was 
observed in cells with deleted FKBP5. 
4.2.5 Inhibition of autophagic flux by HDAC inhibitors 
The striking effects in responsiveness to treatment with psychopharmaca were observed 
with the class of mood stabilisers (chapter 4.2.3). In particular, VPA treatment regulated 
autophagy markers like BECN1 and VPA. Controversial effects of VPA treatment on 
autophagy have been published. Therefore, VPA induced upstream autophagy induction 
in contrast to downstream blockade of autophagosome processing were analysed next. 
Those two effects can be discriminated in a cellular setup with inhibited maturation of 
autophagic vehicles. Autophagosome fusion with lysosomes in the late phase of 
autophagy is dependent on the activity of vacuolar H+ ATPase and can be 
pharmacologically blocked by treatment with Bafilomycin A1 (Yamamoto et al., 1998). 
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In order to determine a Bafilomycin A1 concentration suitable for the induction of an 
autophagic block in the MEF cells, accumulation of LC3-II was analysed by western 
detection in response to increasing concentrations of Bafilomycin A1 (Figure 29). 
Treatment with 3 nM to 30 nM Bafilomycin A1 dose-dependently increased LC3 
conversion. No further increase in LC3 conversion was observed in response to higher 
Bafilomycin A1 concentration. Therefore, the concentration 50 nM Bafilomycin A1, 
which was in the low range of concentrations inducing a plateau of accumulating LC3 
lipidation, was chosen for the pharmacological induction of autophagic blockade in MEF 
cells in the subsequent experiments as additional markers of autophagy. 
 
Figure 29: Induction of autophagic block by Bafilomycin A1. MEF cells were treated with 
increasing concentrations of Bafilomycin A1 for 2 hours. After cell lysis, conversion of LC3 was 
analysed by western detection. Level of LC3-II was quantified and normalised to the level of LC3-I 
from two biological replicates. Conversion in response to Bafilomycin A1 treatment was calculated 
compared to conversion in control treated cells. Dots show the mean value and error bars represent the 
standard error of the mean. 
VPA has been reported to exert at least part of its effects by inhibiting HDACs. In order 
to unravel the role of VPA in modulating autophagy, potential epigenetic effects via 
HDACs were pharmacologically analysed. Therefore, co-treatment with two further 
HDAC inhibitors, butyrate (BUT) and TSA, in cells with pharmacologically blocked 
autophagy was tested for effects on LC3 conversion as well as P62, VPS34 and BECN1 
accumulation.  
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Figure 30: Characterizing the effect of VPA and HDAC inhibitors on the autophagic marker 
LC3. LC3 conversion in MEF was analysed by western detection with correspondent western blots 
shown next to the graphs. Level of LC3-II was quantified and normalised to the level of LC3-I from 
three biological replicates. Autophagy was pharmacologically blocked by co-treatment with 50 nM 
Bafilomycin A1 for 2 hours. Responsiveness to treatment with HDAC inhibitors or growth medium 
starvation in cells with and without autophagic blockade was calculated as ratio of values upon 
treatment divided by the value upon control treatment without autophagy blockade. Responsiveness of 
LC3 conversion to autophagy blockade in combination with treatment with 0.5 mM and 5 mM VPA 
for 48 hours (A), treatment with 5 mM VPA, 2.5 mM BUT and 33 nM TSA for 48 hours (B) or 
exchange of growth medium to HBSS for 4 hours (C) was assessed. Bars show the mean value and 
error bars represent the standard error of the mean. Statistical significances were calculated by a two-
way analysis of variance combined with a Bonferroni post-hoc test and are depicted as follows: * for 
p≤0.05, ** for p≤0.01 and *** for p≤0.001.  
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First, LC3 conversion in combined treatment with increasing concentrations of VPA and 
Bafilomycin A1 was analysed (Figure 30A). Treatment with VPA dose-dependently 
inhibited LC3 conversion in the absence of autophagic blockade. This effect, however, 
was not significant for either 0.5 mM or 5 mM VPA. Treatment with Bafilomycin A1 
significantly increased LC3 conversion due to inhibition of autophagosome maturation. 
This effect was dose-dependently attenuated by treatment with VPA. 
Indeed, treatment with either VPA, BUT or TSA decreased LC3 conversion in a, 
however, non-significant magnitude (Figure 30B). When autophagy was 
pharmacologically blocked, co-treatment with at least TSA significantly attenuated the 
Bafilomycin A1 induced increase in LC3 conversion comparably to co-treatment with 
VPA, hinting to an inhibition of autophagy at an early stage in response to VPA and TSA 
treatment. As an internal control, cells were nutrient-starved by the exchange of growth 
medium to HBSS, which is well known to induce autophagy (Figure 30C). Under 
nutrient starvation, slightly less LC3 conversion was observed. When autophagy was 
pharmacological blocked, HBSS induced starvation, indeed, significantly increased the 
accumulation of lipidated LC3 above the level measured in cells with a pharmacological 
block of autophagy grown in full medium. 
Originally, autophagy was regarded as a non-selective process. Accumulating evidence, 
however, indicates that certain proteins guarantee for selective degradation of many types 
of cargo. Hence, P62 has been identified to target specific cargoes for autophagy 
(Lamark et al., 2009). Lack of autophagy, however, has been shown to result in the 
accumulation of P62 and increased P62 accumulation could therefore serve as a marker 
for inhibited autophagy (Rusten and Stenmark, 2010). In line with an inhibition of 
autophagy at an early stage by VPA, accumulation of P62 was detected when cells were 
treated with 5 mM, but not 0.5 mM VPA (Figure 31A).  
An increase in P62 accumulation as a combined effect of treatment with both 
Bafilomycin A1 and VPA, however, was not observed. Increased P62 accumulation in 
response to VPA treatment was mimicked by treatment with TSA but not with BUT 
(Figure 31B). Combined treatment with Bafilomycin 1 and TSA increased accumulation 
of P62, too. No effect on P62 accumulation was observed in response to nutrient-
starvation induction of autophagy alone or combined with pharmacological blockade of 
autophagy by Bafilomycin A1 (Figure 31C). 
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Figure 31: Characterizing the effect of VPA and HDAC inhibitors on the autophagic marker 
P62. P62 expression levels in MEF cells were analysed by western detection with correspondent 
western blots shown next to the graphs. Level of P62 was quantified and normalised to the level of 
actin from three biological replicates. Autophagy was pharmacologically blocked by co-treatment 
with 50 nM Bafilomycin A1 for 2 hours. Responsiveness to treatment with HDAC inhibitors or 
growth medium starvation in cells with and without autophagic blockade was calculated as ratio of 
values upon treatment divided by the value upon control treatment without autophagy blockade. 
Responsiveness of P62 expression to autophagy blockade in combination with treatment with 0.5 mM 
and 5 mM VPA for 48 hours (A), treatment with 5 mM VPA, 2.5 mM BUT and 33 nM TSA for 
48 hours (B) or exchange of growth medium to HBSS for 4 hours (C) was assessed. Bars show the 
mean value and error bars represent the standard error of the mean. Statistical significances were 
calculated by a two-way analysis of variance combined with a Bonferroni post-hoc test and are 
depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001.  
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Figure 32: Characterizing the effect of VPA and HDAC inhibitors on the autophagic marker 
VPS34. VPS34 expression levels in MEF cells were analysed by western detection with 
correspondent western blots shown next to the graphs. Level of VPS34 was quantified and normalised 
to the level of actin from three biological replicates. Autophagy was pharmacologically blocked by 
co-treatment with 50 nM Bafilomycin A1 for 2 hours. Responsiveness to treatment with HDAC 
inhibitors or growth medium starvation in cells with and without autophagic blockade was calculated 
as ratio of values upon treatment divided by the value upon control treatment without autophagy 
blockade. Responsiveness of VPS34 expression to autophagy blockade in combination with treatment 
with 0.5 mM and 5 mM VPA for 48 hours (A), treatment with 5 mM VPA, 2.5 mM BUT and 33 nM 
TSA for 48 hours (B) or exchange of growth medium to HBSS for 4 hours (C) was assessed. Bars 
show the mean value and error bars represent the standard error of the mean. Statistical significances 
were calculated by a two-way analysis of variance combined with a Bonferroni post-hoc test and are 
depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001.  
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Figure 33: Characterizing the effect of VPA and HDAC inhibitors on the autophagic marker 
BECN1. BECN1 expression levels in MEF cells were analysed by western detection with 
correspondent western blots shown next to the graphs. Level of BECN1 was quantified and 
normalised to the level of actin from three biological replicates. Autophagy was pharmacologically 
blocked by co-treatment with 50 nM Bafilomycin A1 for 2 hours. Responsiveness to treatment with 
HDAC inhibitors or growth medium starvation in cells with and without autophagic blockade was 
calculated as ratio of values upon treatment divided by the value upon control treatment without 
autophagy blockade. Responsiveness of BECN1 expression to autophagy blockade in combination 
with treatment with 0.5 mM and 5 mM VPA for 48 hours (A), treatment with 5 mM VPA, 2.5 mM 
BUT and 33 nM TSA for 48 hours (B) or exchange of growth medium to HBSS for 4 hours (C) was 
assessed. Bars show the mean value and error bars represent the standard error of the mean. Statistical 
significances were calculated by a two-way analysis of variance combined with a Bonferroni post-hoc 
test and are depicted as follows: * for p≤0.05, ** for p≤0.01 and *** for p≤0.001.  
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VPS34 is the only class III phosphoinositide 3-kinase in mammals, phosphorylating 
phosphatidylinositol to produce phosphatidylinositol 3-phosphate (Volinia et al., 1995). 
Phosphatidylinositol 3-phosphate production has been implicated in promoting 
autophagy (Backer, 2008). In line with the assumption of a VPA induced inhibition of 
autophagy at an early stage, decreased levels of VPS34 were detected in cells with 
pharmacologically blocked autophagy in response to co-treatment with 5 mM but not 
0.5 mM VPA (Figure 32A). A similar effect was detected in response to co-treatment 
with BUT (Figure 32B). Decreased levels of VPS34 were also observed in response to 
treatment with BUT or TSA. No effect on VPS34 expression level was observed in 
response to nutrient-starvation induction of autophagy alone or combined with 
pharmacological blockade of autophagy by Bafilomycin A1 (Figure 32C). 
Next, the expression of BECN1 in response to pharmacologic blockade of autophagy and 
treatment with HDAC inhibitors was analysed. Bafilomycin A1 induced blockade of 
autophagy itself had not effect on the expression level of BECN1 (Figure 33A). When 
co-treated with 5 mM VPA, however, Bafilomycin A1 decreased expression levels of 
BECN1. Upregulation of BECN1 in response to treatment with VPA as reported in 
section 4.2.3 was not recapitulated in this experiment. BECN1 levels were also not 
responsive to treatment with either BUT or TSA. Induction of autophagy by nutrient-
starvation increased expression levels of BECN1 when autophagy was blocked 
pharmacologically. 
4.2.6 Induction of transcriptionally controlled autophagy by VPA 
As shown in chapter 4.2.4, transcriptional activity upstream of a FOXO3α responsive 
promoter was markedly increased in response to treatment with VPA. Interestingly, 
FOXO3α activity has been shown to correlate with increased transcription of several 
genes involved in autophagy (Feng et al., 2015; Mammucari et al., 2007).  
Pharmacological regulation of FOXO3α activity could therefore provide a potential 
mechanistic link how VPA modulates autophagy on the transcriptional level. In order to 
test this hypothesis, the expression levels of five genes, which are controlled by FOXO 
transcription factor signalling and exert key roles in regulation of autophagy, were 
checked. The five selected genes have been shown to regulated autophagy at different 
stages with initiation of autophagy being affected by ULK1, BECN1, and VPS34, 
autophagosome formation being regulated by ATG5 and autophagosome maturation 
being controlled by LC3. Transcription of the genes was analysed in response to 
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treatment with VPA in comparison to treatment with the two additional HDAC inhibitors 
BUT and TSA (Figure 34). 
 
Figure 34: Transcriptional regulation of FoxO3α responsive autophagy related genes by VPA 
and HDAC inhibitors. mRNA levels of selected autophagy related genes (as indicated in A – E) in 
MEF cells was analysed by qRT-PCR. Level of target gene mRNA was quantified and normalised to 
the mRNA level of HPRT from three biological replicates in technical duplicates. Responsiveness to 
treatment with 5 mM VPA, 2.5 mM BUT and 33 nM TSA was calculated as ratio of values upon drug 
treatment divided by the value upon control treatment. Bars show the mean value and error bars 
represent the standard error of the mean. Statistical significances were calculated by a one-way 
analysis of variance combined with a Bonferroni post-hoc test and are depicted as follows: * for 
p≤0.05, ** for p≤0.01 and *** for p≤0.001. 
Treatment with VPA significantly increased the transcription of VPS34, ATG12 and 
LC3, while the increase in transcription of ULK1 and BECN1 was not significant. A 
similar profile of transcriptional enhancement was also observed in in response to 
treatment with BUT, with significantly enhanced levels of ATG12 and LC3. In contrast, 
no significant changes in mRNA levels of the five autophagy genes was detected in 
response to treatment with TSA. 
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5 Discussion 
It has become widely recognised that dysregulation of the stress hormone system as a 
consequence of excessive exposure to stress is a major factor for developing stress-
related psychiatric diseases. A regulatory component of this system, FKBP5, was 
detected as a genetic risk factor. Indeed, FKBP5 has been shown to be part of an 
intracellular ultra-short negative feedback loop that regulates GR receptor activity. 
Besides regulation of GR receptor activity, recent studies reported additional effects of 
FKBP5. On this basis, effects of FKBP5 on gene transcription as well as on activity of 
selected kinases were analysed in this thesis. 
5.1 GLO1 gene duplication in FKBP5-KO mice 
FKBP5 dependent effects on global gene transcription were analysed in an unbiased 
approach using RNA microarrays. Besides downregulation of FKBP5 transcription, 
which is presumably due to altered chromatin architecture as a result of the truncated 
FKBP5 gene or to nonsense-mediated decay of the mutated FKBP5 mRNA (Baker and 
Parker, 2004), the transcription of the three genes FGD2, GLO1 and RBM12 was found 
to be upregulated in FKBP5-KO animals. Upregulation could not be verified by RT-PCR 
for RBM12. It could finally be shown that increased GLO1 mRNA and protein levels are 
caused by a genetic copy number variance of GLO1 co-segregated with the FKBP5 
alleles. The FGD2 gene is located in close proximity to the FKBP5 and GLO1 loci and 
increased FGD2 mRNA is very likely due to cis genetic alterations in mice carrying the 
FKBP5 deletion and the GLO1 duplication. 
In the process of generating a knock out mouse line with the conventional technique of 
homologous recombination, i.e. the replacement of an endogenous gene by a truncated or 
mutated homologue in a donor stem cell, mice with different genetic background are 
used. Embryonal stem cells are usually isolated from blastocysts of mice from the 129 
strain and subsequently genetically modified, selected for the modification and inserted 
into the blastocyst of a foster mouse. Resulting new-born chimeric mice with gonads 
originating from the modified stem cell are crossbred with mice of the desired genetic 
background for breeding and phenotyping. As the two inbred mouse lines used as stem 
5.1 GLO1 gene duplication in FKBP5-KO mice 
 
90 
  
cell donor and genetic background donor differ in their genetic endowment, at least ten 
rounds of back crossing are required as good laboratory praxis and generally considered 
sufficient to generate a homogeneous genetic background (Silva et al., 1997). In each 
breeding round, mice are segregated according to their deleted or non-deleted version of 
the gene of interest with the deleted version originating from the stem cell donor and the 
wild type version originating from the back crossing mice. Genetic variances in close 
genetic proximity to the gene of interest, however, co-segregate with the gene of interest 
as the rate of crossing over is a function of how close the genes are to each other on a 
given chromosome. The phenomenon which is caused by the genetic linkage of genetic 
variances with the gene of interest is called flanking gene problem (Crusio, 2004).  
In the last two decades, research based on genetically engineered mice has become 
indispensable for studying gene function in a mammalian animal model. After the 
establishment of the conventional knockout strategy, it took several years until it was 
noticed that there was a systematic bias inherent to this strategy: genes flanking the 
induced null mutation would also be homozygous for alleles derived from the ES cell 
donor in homozygous knockout mutants (Gerlai, 1996). This is inevitable, because it is 
due to the different genetic background of the mutant and the wild type version of the 
targeted gene. The flanking gene problem in a newly designed knockout mouse model 
can be circumvented using a gene knockout strategy based on the Cre/loxP system, if the 
Cre recombinase constitutively expressing mice are controlled for the flanking gene 
problem or if the Cre recombinase is activated pharmacologically, e.g. in a tetracycline- 
or tamoxifen-controlled setting of the Cre recombinase transcriptional activation. 
Furthermore, the possibility to directly target an embryo of any available genetic 
background by microinjection of RNAs using the CRISPR/Cas9 system redundantises 
the detour of crossbreeding subsequent to targeting of ES cells from the 129 strain (Singh 
et al., 2015). 
Here, due to the flanking gene problem, the FKBP5 knockout mouse model is affected by 
a copy number variance in the GLO1 gene resulting in higher GLO1 expression in 
FKBP5-KO mice. The GLO1 gene is located approximately 2 Mb upstream of the 
FKBP5 gene on chromosome 17 in mice. Although recombination rates vary between 
genomic loci, the assumption is made that 1 centimorgan corresponds to approximately 
2 Mb on average in mice (Jensen-Seaman et al., 2004). This would mean that there is a 
1 % chance that a marker at one genetic locus on a chromosome will be separated from a 
marker at a second locus by crossing over in a single generation, if the two markers are 
2 Mb apart from each other. Therefore, a 1 % chance of homologous recombination 
event during meiosis is expected, which results in a chromosomal arrangement of a 
deleted FKBP5 allele next to a single copy of GLO1. Thus there would approximately be 
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one in a hundred FKBP5-HET offspring without the GLO1 duplication. Experimental 
FKBP5-KO mice are bred from two parental FKBP5-HET mice, each of them being 
liberated from the GLO1 duplication by a chance of 1 %. Thus, there is an approximately 
0.01 % total chance of an FKBP5-KO offspring mouse without the GLO1 gene 
duplication. In other words, even after several rounds of breeding, there is little chance 
that the GLO1 duplication in FKBP5-KO mice is lost due to homologous recombination 
events. The FKBP5 mouse model therefore provides an example where a genetic 
variance in close proximity to the knock out allele, i.e. the GLO1 duplication, might 
potentially influence the phenotype. 
Interestingly, one of the FKBP5-KO mice showed only one copy of the GLO1 
duplication in our genotyping assay. This mouse very likely has one chromatid with the 
GLO1 duplication and the sister chromatid without the duplication (Figure 4A).  
The Glo1 gene has been described to influence anxiety-related behaviour (Distler and 
Palmer, 2012). No overt anxiety related behaviour, however, was observed in the FKBP5 
knockout mouse model (Hartmann et al., 2012; Touma et al., 2011). In a study using 
BAC transgenic mice, GLO1 overexpression caused increased anxiety-related behaviour 
(Distler et al., 2012). This effect, however, was only observed in mouse lines with the 
highest copy numbers. It seems therefore plausible that the increased GLO1 protein level, 
which is very likely due to the duplication of GLO1 in FKBP5-KO animals, might not be 
high enough to induce an overt anxiety phenotype. The GLO1 status should nevertheless 
be taken into consideration when interpreting data from FKBP5 knockout mice and 
descending cells.  
Noteworthy, FGD2, the gene showing the most significant upregulation of gene 
expression in the microarray (Figure 1), is located in between the loci coding for FKBP5 
and GLO1 on mouse chromosome 17. Although the analysed copy number variance for 
the GLO1 spanning region does not contain the FGD2 gene, a cis genetic effect 
underlying the upregulation of the FGD2 gene cannot be excluded. For example, the 
deletion of FKBP5 as well as the duplication of the GLO1 spanning locus could change 
the chromatin structure and hereby modulate the transcription of FGD2. The deletion in 
FKBP5 is 0.8 Mb and the duplication border of the GLO1 spanning region 1.3 Mb apart 
from the FGD2 gene. It is possible that those alterations are sufficient to modify DNA 
looping responsible for FGD2 transcriptional initiation, elongation and termination 
(Mercer and Mattick, 2013). Alternatively, the chromosomal region around GLO1 might 
provide a potential hub for duplication events. In analogy to the postulated origin of the 
GLO1 copy number variance by a non-allelic homologous recombination event, a second 
independent non-allelic homologous recombination event might have generated a 
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duplication of the FGD2 spanning region in the stem cell donor mice 129SvJ mouse line 
(Hastings et al., 2009). Given the possibility that genomic rearrangements are responsible 
for the differences of FGD2 mRNA in the FKBP5 knockout mouse model, a functional 
link between FKBP5 and FGD2 was not further explored.  
5.2 The role of FKBP5 in modulating cellular pathways used by psychopharmaca 
 
93 
 
5.2 The role of FKBP5 in modulating cellular pathways 
used by psychopharmaca 
It remains elusive why more than half of the patients with major depressive disorder do 
not fully respond to the treatment with a first antidepressant (Trivedi et al., 2006). While 
switching antidepressants is a common strategy for treatment of non-responder patients, 
clinicians could benefit from further knowledge about the actions of different 
antidepressants. Understanding the molecular mechanisms how different antidepressants 
exert beneficial effects over a variety of drug targets might improve targeting and 
efficacy in the use of existing antidepressants. In addition, identification of molecular key 
players in pathways, which are convergently targeted by a majority of existing 
antidepressants, could serve as entry to the development of novel target-specific drugs for 
the treatment of stress-related psychiatric diseases. 
First evidence for a role of FKBP5 in antidepressant response came from genetic studies 
(Binder et al., 2004). A recent study in our group further discovered that FKBP5 
enhanced autophagy to synergise with antidepressant action of a TCA and two SSRIs 
(Gassen et al., 2014). A further study in our group showed that FKBP51 inhibited 
GSK3β and augmented the effects of psychotropic medications with a mood stabiliser 
and an SSRI (Gassen et al., 2015).  
The findings of these studies drew the interest to analyse a broad list of psychopharmaca 
for their effects evoked on those pathways. Therefore, expression and phosphorylation 
levels of proteins presumably targeted by antidepressant treatment were analysed in this 
thesis. In response to treatment with 13 psychopharmaca from different drug classes and 
two experimental substances, general effects evoked by antidepressant treatment as well 
as synergistic effects of FKBP5 in response to antidepressant treatment were analysed on 
cellular pathways that previously had been shown to be affected by treatment with certain 
antidepressants. Therefore the expression, the phosphorylation and the activity of those 
proteins were compared in MEFs with functional and deleted FKBP5. 
These pathways were heterogeneously affected by different psychopharmaca, with 
members of the same psychopharmaca class not stringently evoking similar effects. The 
most pronounced effects were observed in response to treatment with the mood 
stabilisers LIT and, in particular, VPA. FKBP5 generally determined ERK 
phosphorylation in response to psychopharmaca action. Responsiveness of GSK3β and 
AKT phosphorylation as well as regulation of downstream targets was partially affected 
by FKBP5. 
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5.2.1 Choice of cellular system 
Genetically manipulated knockout mouse lines have become an invaluable tool for 
defining the function of genes in a physiological context. Ex-vivo culturing of cells, 
however, enables simple and fast experimental manipulation by extensive drug treatment 
and overexpression of proteins. Hence, isolated and cultured mutant cells from 
genetically manipulated knockout mouse lines are valuable tools for studying the 
mechanistic function of genes. The major drawback of primary tissue, which have to be 
isolated from embryonic donor animals, can be circumvented by the immortalisation of 
primary cells. Transforming or passaging primary fibroblasts from embryonal mice into 
MEFs with permanent growth features is well established.  
In this work, MEFs from mice with or without deleted FKBP5 were utilised as cell 
system to study the function of FKBP5 in psychopharmacologically targeted pathways. 
FKBP51 is strongly expressed in MEF cells with functional FKBP5 providing a great 
difference in FKBP5 levels in comparison to cells with deleted FKBP5. The pathway 
analysis in FKBP5-expression-rescued MEFs, facilitated by the ectopic expression of 
FKBP5 in cells with deleted FKBP5 and comparison with their parent mutant cells, was 
experimentally not accessible due to low transfection efficiency in those MEFs. 
Moreover, pathway analysis in MEFs might not fully reflect the regulation of pathways 
by psychopharmaca treatment in a physiological context. Differential proteomic profiles 
of cell types might account for the absence of psychopharmaca evoked effects in MEFs. 
5.2.2 Cell viability in response to treatment 
It is plausible that antidepressants exert their actions in a dose dependent matter, either 
applied in clinics or in cell culture. Nevertheless, drug dosage cannot easily be converted 
from clinics to cell culture in particular due to different pharmacokinetics. Without the 
prior knowledge of molecular markers of drug effectiveness, a two-sided appraisal has to 
be made for the selection of appropriate drug concentrations in cell culture. On the one 
hand, relevant drug effects are likely to be overseen when drug concentrations are too 
low. On the other hand, disproportionately high drug concentrations might activate, 
amongst others, pathways of toxicity, which may confound changes induced in pathways 
relevant for treatment.  
It appears to be current practice in cell culture, however, to apply antidepressants of the 
classes of TCAs, SSRIs, SSNRIs and atypical antidepressants at a standard concentration 
of 10 µM. In order to at least exclude toxic effects in the analysis of posttranslational 
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protein modification analysed in response to treatment, two orthogonal methods were 
assessed to measure cell viability in response to treatment. In a first step, the toxicity of 
13 antidepressants as well as two additional experimental drugs was therefore analysed 
with the two viability assays, the MTT assay and the LDH assay at three time points of 
the exposure. 
Data from MTT and LDH assays concordantly indicated slight effects on viability at drug 
concentrations of 10 µM, when cells were treated with either the two SSRIs FLX and 
PRX or the SSNRI VTX for 48 hours. Differing from the standard concentration of 
10 µM, FLX, PRX and VTX were therefore applied at a slightly lower concentration of 
3 µM as standard concentration. In response to treatment with DXP, however, viability 
started to be decreased at slightly higher concentrations compared to other 
antidepressants. Differing again from the standard concentration of 10 µM, DXP was 
used at a concentration of 30 µM. Correspondently established standard concentrations 
for the application of mood stabilisers, the anaesthetic KTM, and the two experimental 
drugs in cell culture were not found in the literature. Therefore subtoxic concentrations 
were chosen derived from the two viability assays. 
Interestingly, a concentration dependent increase in MTT signal was detected as a 
characteristic feature of eight of the 13 antidepressants and one of the two experimental 
drugs. The characteristic increase in MTT signal, however, which could be 
misinterpreted as increase in cell viability, was not accompanied by an increase in LDH 
signal. Concordantly for most drugs, the concentration dependent increase in MTT signal 
was arising after 12 hours, most pronounced after 24 hours and diminished after 48 hours 
treatment. Certainly, the MTT assay is an indirect measure of cell viability. The exact 
cellular mechanism of MTT reduction into formazan is not completely understood, but 
likely involves reaction with NADH or similar reducing molecules that transfer electrons 
to MTT (Marshall et al., 1995). Speculation in the early literature involving specific 
mitochondrial enzymes has led to the assumption that MTT is measuring mitochondrial 
activity (Berridge and Tan, 1993). Antidepressants have been shown to influence 
mitochondrial function and particularly mitochondrial respiratory chain complex activity 
(Abdel-Razaq et al., 2011; Hroudova and Fisar, 2010; Scaini et al., 2011). Therefore, 
care has to be taken when interpreting MTT data in response to treatment with drugs that 
might interfere with mitochondrial activity. Increased signals in MTT but not in LDH test 
observed for subtoxic concentrations of CTP, PRX, VTX, AMT, DXP, CLP, LMT and 
LIT hint to augmented metabolism or mitochondrial activity in response to treatment at 
certain concentration of these drugs. Interestingly, augmented metabolism was also 
observed in response to treatment with subtoxic concentrations of CHI. This is in line 
with a recent report that described the involvement of mitochondrial GSK3β in 
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production of redox equivalents via regulation of NADH:ubiquinone oxidoreductase 
(complex I) (King et al., 2008). Of note, mitochondrial dysfunction has been linked to the 
pathophysiology of depression (Karabatsiakis et al., 2014). Treatment with subtoxic 
concentrations of CTP, PRX, VTX, AMT, DXP, CLP, LMT and LIT appears to interfere 
with mitochondrial activity. With eight of 13 drugs increasing mitochondrial activity as 
represented by the MTT signal, a causative contribution of the observed effect in clinical 
effectiveness might be possible. 
5.2.3 Partial FKBP5 dependence of psychopharmaca action on 
pathways  
In two recent publications, we could show that the FKBP5 status determined the 
responsiveness of certain drugs on both cellular pathway and stress related coping 
behaviour (Gassen et al., 2014, 2015). In contrast, pure genotype effects on behaviour 
have not been observed in mice with deleted FKBP5 (Touma et al., 2011). In the analysis 
of cellular pathways in MEF cells with deleted FKBP5 compared to MEF cells with 
functional FKBP5, however, a differential protein status was detected in suspected 
targets of FKBP51. Phosphorylation of ERK and AKT was enhanced in cells with 
deleted FKBP5. A mechanism for FKBP51 mediated dephosphorylation was recently 
provided with the characterisation of the recruitment of PHLPP phosphatase to AKT by 
FKBP51 (Pei et al., 2009). A similar scenario could underlie the enhanced 
phosphorylation of ERK in cells with deleted FKBP5. Increased phosphorylation of 
AKT, however, did not impact on FOXO3a phosphorylation at Ser-318 and Ser-321 or 
FOXO3α activity. Autophagy appeared slightly enhanced in cells with deleted FKBP5 as 
indicated by increased levels of the autophagy initiator BECN1 and augmented 
conversion of LC3-II/I. Distinct regulation of the GSK3β pathway was not detected in 
cells with deleted FKBP5, which is in line with the unchanged phosphorylation of 
GSK3β detected in the hippocampus from mice with deleted FKBP5 (Gassen et al., 
2015). 
Responsiveness of the pathways analysed in this work did not generally depend on the 
presence of FKBP5. Responsiveness of certain targets, however, was dependent on 
FKBP5. Most markedly, responsiveness of ERK phosphorylation to psychopharmaca 
treatment in cells with functional FKBP5 was abolished in cells with deleted FKBP5. In 
cells with functional FKBP5, treatment with psychopharmaca increased phosphorylation 
up to five fold. This is in the range of the increase of  ERK phosphorylation detected in 
untreated cells devoid of FKBP5 in comparison to WT cells. This hints to a two partied 
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mechanism of FKBP51 adjusted ERK phosphorylation, where on the one hand, the 
presence of FKBP51 decreased the phosphorylation of ERK and on the other hand, 
psychopharmaca evoked increases in ERK phosphorylation depended on the presence of 
FKBP51. However, it is also possible that ERK was extensively phosphorylated in cells 
with deleted FKBP5, thus precluding a further increase in ERK phosphorylation by the 
treatment with psychopharmaca. Differential effects with regard to FKBP5 were also 
evoked for VPA dependent TCF/LEF and FOXO3α activity, with enhanced effects in 
cells with deleted FKBP5. Similarly, enhancement of TCF/LEF activity was detected in 
response to HDAC inhibitor TSA and enhancement of FOXO3α activity in response to 
the AKT inhibitor TCB. Effect sizes in cells with deleted FKBP5, however, could hardly 
be attenuated by the rescue of the FKBP5 expression status via transient transfection. 
This hints to a cell line dependent effect in responsiveness of FOXO3α to HDAC 
inhibitors, which was not directly caused by the FKBP5 deletion. Presumably, 
differential transfection efficiencies in cells with deleted and functional FKBP5 
contributed to heterogeneous expression of reporter gene constructs and therefore 
differential TCF/LEF activity. 
5.2.4 Common effects of psychopharmaca treatment  
SSRIs and TCAs 
A more homogeneous pattern was observed for the regulation of cellular pathways by the 
three SSRIs (CTP, FLX, and PRX) and the three TCAs (AMT, DXP, and CLP) in the 
MEF model.  
Treatment with neither SSRIs nor TCAs did generally affect GSK3β phosphorylation and 
regulation of its reported downstream targets BCAT and CRMP2. Slight inhibition of 
TCF/LEF activity was detected in response to treatment with PRX and CLP. In both 
brain tissue from mice and cortical astrocytes from rat, treatment with the SSRI PRX 
increased the phosphorylation of GSK3β (Gassen et al., 2015). Increased 
phosphorylation of GSK3β in response to treatment with PRX was reflected by an 
increase in TCF/LEF activity in cortical astrocytes. The concentration of PRX used for 
treatment of astrocytes, however, was higher than the concentration used in this work.   
Modulation of ERK phosphorylation in response to treatment was not detected in 
response to 48 hour treatment with neither SSRIs nor TCAs in MEF cells with the 
exception that CTP induced ERK phosphorylation in cells with functional FKBP5. In 
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contrast, a cell-specific decrease of ERK phosphorylation was observed in response to 
acute treatment with a SSRI and a TCA in mice (Di Benedetto et al., 2013). As the ERK 
pathway is well known to transduce fast answers in response to environmental stimuli, 
usually acute effects on ERK phosphorylation are analysed. A study analysing chronic 
treatment effects in response to a SSRI and a TCA found both increased and decreased 
ERK phosphorylation depending on the localisation of ERK in different intracellular 
compartments (Fumagalli et al., 2005).  
AKT phosphorylation was increased in response to treatment with SSRIs and partially 
TCA. Increased AKT activity, however, was not reflected by regulation of FOXO3α 
phosphorylation and activity as well as modulation of levels of the autophagy initiator 
BECN1. Regulation of autophagy in response to treatment with SSRIs and TCAs was 
indicated by an increased ratio of LC3-II/I. In principle, increased ratio of LC3-II/I can 
be caused by either enhanced production of LC3-II or by blockade of degradation of 
autophagic cargo, thereby inhibiting the removal of LC3-II (Gassen et al., 2014; Rossi et 
al., 2009; Zschocke et al., 2011). In brains from animals with functional, but not deleted, 
FKBP5, acute treatment with the SSRI PRX or the TCA AMT had led to 
dephosphorylation of AKT, accumulation of BECN1 and enhanced conversion of LC3-
II/I (Gassen et al., 2014). In mice, acute treatment increased autophagy presumably via 
inhibition of AKT and FKBP51 mediated action of AKT on BECN1 (Gassen et al., 2014; 
Wang et al., 2012). In MEFs, in contrast, data from this work hint to a regulation of 
LC3-II/I conversion in response to treatment with SSRIs and TCAs, which is 
independent of AKT phosphorylation and BECN1 levels.  
SSNRIs and the atypical antidepressant TNP 
The pattern of the regulation of cellular pathways in the MEF model was very similar for 
the two SSNRIs (VTX and VNF) and the atypical antidepressants (TNP).  
In general, treatment with neither SSNRIs nor the atypical antidepressant affected 
GSK3β phosphorylation and regulation of its downstream target BCAT. Out of the three 
drugs, only TNP increased CRMP2 phosphorylation in cells with deleted FKBP5. In cells 
with functional FKBP5, TCF/LEF activity was inhibited in response to treatment with 
VTX. Regulation of CRMP2 phosphorylation as well as TCF/LEF activity by 
psychopharmaca may not uniquely be regulated by GSK3β, explaining modulation of 
downstream targets in the absence of effects on GSK3β activity. 
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Treatment with SSNRIs and the atypical antidepressant increased the phosphorylation of 
ERK in cells with functional FKBP5. As mentioned above, ERK phosphorylation did not 
respond to treatment with the drugs in cells with deleted FKBP5. 
AKT phosphorylation was not affected by treatment with SSNRIs or the atypical 
antidepressant. Moreover, the drugs did not modulate the phosphorylation and activity of 
FOXO3α. Likewise, BECN1 levels did not change in response to treatment with the 
drugs. VTX increased the conversion of LC3-II/I irrespectively of FKBP5, whereas VNF 
and TNP did not modulate LC3-II/I conversion. As observed with SSRIs and TCAs, 
regulation of LC3-II/I conversion by SSNRIs and TNP seems to be uncoupled from 
FKBP5 dependent regulation of BECN1 by AKT. 
Mood stabiliser 
In respect of structure, the group of mood stabiliser (VPA, LMT, and LIT) was 
comprised by highly diverse psychopharmaca. All the more surprising, a more or less 
common pattern was observed in the regulation of cellular pathways in response to 
treatment with the mood stabiliser in the MEF model. This pattern, in turn, diverged from 
the patterns evoked by other classes of psychopharmaca analysed in this work. 
GSK3β is discussed as a central modulator in mood regulation and a well-known target 
of psychopharmacological treatment with LIT (Li and Jope, 2010). In line, increased 
phosphorylation as indicator of inhibited GSK3β activity was detected in response to 
treatment with LIT and LMT and also CHI, but not VPA, solely in cells with functional 
FKBP5. This is in line with the observation that treatment with LIT only increased 
phosphorylation of GSK3β in tissue from mice with functional FKBP5 (Gassen et al., 
2015). Inhibition of GSK3β activity in response to treatment with the mood stabilisers or 
CHI resulted in reduced phosphorylation of its target CRMP2. Furthermore, inhibited 
GSK3β activity in response to treatment with the mood stabiliser LIT and VPA or CHI 
was reflected by, however non-significantly, increased TCF/LEF activity but not by 
increased BCAT levels, hinting to an activation of Wnt signalling, which was not 
detectable on the level of BCAT. Recently, we also had shown that treatment with either 
VPA or LIT increased TCF/LEF activity with different significance in neurons and 
cortical astrocytes from rats (Gassen et al., 2015). VPA is a well-known activator of Wnt 
signalling (Blaheta and Cinatl, 2002). In contrast to activation of Wnt signalling by LIT, 
activation of Wnt signalling by VPA is proposed to be independent of GSK3β and rather 
be based on activation of Wnt dependent gene expression through inhibition of HDACs 
(Phiel et al., 2001). This is reflected by a non-significant decrease in GSK3β 
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phosphorylation and BCAT stability countered by increased TCF/LEF activity in 
response to treatment with VPA observed in this work. 
Treatment with the three mood stabiliser markedly increased the phosphorylation of ERK 
in cells with functional FKBP5. This effect was abolished in cells with deleted FKBP5. 
The ERK pathway has recently been reported to be under control of LIT, with 
dependency of LIT effects on both GSK3β and ERK (Zassadowski et al., 2015). In line, 
ERK2 phosphorylation was highly sensitive to GSK3β inhibition by CHI in this work. 
Increased ERK phosphorylation in response to treatment with VPA observed in this work 
is in line with numerous reports underlining its role in activation of the ERK pathway 
(Blaheta and Cinatl, 2002).  
Mood stabilisers did largely not affect AKT phosphorylation, its downstream targets and 
autophagy. Only LMT increased AKT phosphorylation, and solely in cells with 
functional FKBP5, which was again not reflected on the level of BECN1. GSK3β has 
been reported to be inactivated by AKT (Woodgett, 2005). This hints to an indirect effect 
in inhibition of GSK3β via activation of AKT in response to treatment with LMT, as 
described earlier. Phosphorylation of FOXO3α at the suspected AKT target site was also 
not affected by treatment with mood stabilisers. 
Both AKT and ERK regulate FOXO3 activity via specific phosphorylation and 
subsequent ubiquitination and degradation (Yamaguchi et al., 2012). Ubiquitination by 
SKP2 has been shown to be dependent on AKT induced phosphorylation and 
ubiquitination by MDM2 on ERK induced phosphorylation. Interestingly, increased 
activity of FOXO3α was detected in response to treatment with VPA and LIT. Hence, the 
induction of FOXO3α transcriptional activity in response to treatment with VPA or LIT 
is not caused by either AKT or ERK dependent phosphorylation of FOXO3α, which is 
reported to inhibit FOXO3α transcriptional activity. 
NMDA receptor antagonists 
KTM and other NMDA receptor antagonists have been reported to inhibit GSK3β 
whereas phosphorylation of AKT at Ser-473 remained unchanged (Iadarola et al., 2015; 
Miller et al., 2014). Within this work, however, treatment with KTM or LNC did not 
regulate the phosphorylation of GSK3β and AKT. Missing expression of NMDA 
receptor in fibroblast could prevent the action of KTM and LNC on targets downstream 
of NMDA receptor signalling (Miller et al., 2014). Expression, phosphorylation and 
activity of GSK3β and AKT downstream targets BCAT, TCF/LEF, CRMP2, FOXO3α, 
BECN1 and LC3-II/I was also not affected by treatment with the two NDMA receptor 
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antagonists, with the exception that LNC decreased phosphorylation of CRMP2 in cells 
with deleted FKBP5. 
The phosphorylation of ERK, however, was enhanced in response to treatment with 
KTM in cells with functional FKBP5. As observed in treatment with other 
psychopharmaca, this effect was abolished in cells with deleted FKBP5. The action of 
KTM on ERK phosphorylation appears not to depend on NMDA receptor signalling. 
Both KTM and LNC are considered to exert non-selective NMDA channel blocking 
activities (Zarate et al., 2013). Interestingly, LNC did not enhance ERK activation 
hinting to a mechanism beyond NMDA receptor signalling unique for KTM. 
5.2.5 Regulation of autophagy by VPA 
Recent research has illustrated a link from autophagy to neurotransmission, which likely 
modulates neuronal network dynamics and, ultimately, behaviour (Hernandez et al., 
2012; Kim et al., 2012). Interestingly, HDACs have recently been shown to suppress 
autophagy (Cao et al., 2011). Strikingly, the effects in regulation and activity of 
autophagy markers LC3 and FOXO3α with VPA were opposite to the ones observed 
with other psychopharmaca, here. Treatment with VPA did not increase but decrease the 
ratio of the autophagic marker LC3-II/I and attenuated the accumulation of LC3-II upon 
blockade of autophagy processing. Together, this hints to a slowed down autophagy with 
VPA treatment with decreased conversion of LC3-II/I. 
Treatment with VPA increased the transcriptional activity of FOXO3α. A two-partied 
function in regulation of autophagy has been discussed for FOXO transcription factors. 
On the one hand, activity of FOXO3α has been reported to be controlled by the 
rapamycin independent mTOR complex, mTORC2, which itself is under the control of 
upstream autophagy signalling (Feng et al., 2015). On the other hand, the regulation of 
autophagy by FOXO proteins on a transcriptional level has been described in various cell 
types with transcription of several key players of autophagy being controlled by FOXO 
transcription factors (Feng et al., 2015).  
ATG12, BECN1, LC3, ULK1, and VPS34 are amongst the genes that are controlled by 
FOXO signalling (Feng et al., 2015). Transcription of autophagy genes being involved in 
regulation of late-early (VPS34), late-intermediate (ATG12) and delayed (LC3) 
autophagy but not in early (ULK1, BECN1) autophagy was induced in response to 
treatment with VPA as observed in this work. A similar profile of transcription regulation 
of suspected FOXO target genes was observed in response to treatment with BUT, with 
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transcription induction of late-intermediate (ATG12) and delayed (LC3) autophagy 
genes. In contrast to the HDAC inhibitors VPA and BUT, no effect on the transcription 
on the suspected FOXO target genes was detected in response to treatment with the 
HDAC inhibitor TSA.  
Studies have shown that early life stress can influence the expression of HDAC enzymes 
in the murine brain (Levine et al., 2012; Tesone-Coelho et al., 2015). HDAC enzymes 
lead to more condensed chromatin structure and a less transcriptionally active chromatin 
structure. In addition, an age dependent inversive expression of histone modifying 
enzymes in response to early life stress was found. Animals that were exposed to early 
life stress showed a decreased expression of HDACs in youth and an increased 
expression of HDACs in adultness (Suri et al., 2014). 
HDAC inhibitors are classified in respect to their chemical structure as well as their 
HDAC target selectivity. VPA and BUT are short-chain fatty acids that show in vitro 
potency against classes I and classes II HDACs in the millimolar range (Grayson et al., 
2010). TSA is composed of a hydroxamate structure and shows in vitro potency against 
classes I and classes II HDACs in the nanomolar range (Grayson et al., 2010). VPA is an 
established psychopharmacon that has been used as an anti-convulsant, mood stabiliser, 
and adjuvant treatment for schizophrenia. Treatment with BUT has been reported to exert 
antidepressant-like properties in the mouse (Schroeder et al., 2007). Experimental or 
clinical evidence for the effectiveness of TSA in stress related diseases, however, is 
lacking.  
This work showed that autophagy is not a general feature of HDAC inhibitors. Of note, 
only HDAC inhibitors that were shown to regulate autophagy in this work, are known to 
be active in stress related diseases. It cannot be excluded that the underlying mechanism 
involves HDACs, but HDAC inhibition alone appears not to be sufficient. 
5.2.6 Regulation of treatment outcome by antidepressants 
Overall, the provided data hint to non-linear pathway connections of proteins affected by 
antidepressant treatment. Considering the only rudimentally understood molecular 
mechanism by which antidepressants act, at least the pathways analysed in this work 
appear to be uniquely regulated by different psychopharmaca treatments and FKBP5 
status (Figure 35). It remains, however, unclear to what extent single pathways contribute 
to overall treatment outcome. In line with this, additional pathways are very likely to be 
targeted by psychopharmaca treatment and be involved in conveying treatment outcome. 
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Figure 35: Simplified sketch of molecular pathways underlying psychopharmaca induced 
treatment outcome. Antidepressant treatment modulates the protein status of certain pathways 
leading to re-adaption of cellular function and hence treatment outcome. Unique patterns of protein 
modulation in response to treatment with a certain antidepressant appear to underlie the effectiveness 
of treatment outcome in regard to the environment shaped framework of gene activity. 
Antidepressants are represented by black circles. Pathway proteins and cellular functions are 
represented by black boxes. Unlabeled boxes represent to be discovered pathways and cellular 
functions. 
Non-linearity of pathway connections can be exemplified by the regulation of BCAT, 
which was not significantly regulated by antidepressant treatment. BCAT is 
phosphorylated by GSK3β, which itself is inhibited by ERK and AKT. Phosphorylation 
of BCAT by GSK3β facilitates β-TrCP dependent ubiquitination and proteasomal 
degradation of BCAT. Moreover, BCAT is at a further site also directly phosphorylated 
by AKT, thus exerting a stabilising effect on BCAT (Yamaguchi et al., 2012). As 
observed in this work, treatment with psychopharmaca exerted differential effects on the 
activity of the three kinases GSK3β, ERK, and AKT in a more or less psychopharmaca 
class-dependent manner. With the three kinases being regulated by psychopharmaca 
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treatment, BCAT could serve as a hub for the integration of upstream pathway signals 
elicited by psychopharmaca treatment. 
Likewise, the activity of a certain pathway is likely to excel other pathways in response 
to external stimuli or as maladaptive process in response to prolonged stressors, leading 
to imbalances in the molecular network and symptoms of stress related diseases. The 
regulation of FKBP51 by glucocorticoids likely links all the molecular actions of 
FKBP51 to stress (Hubler and Scammell, 2004; Klengel et al., 2013). With pathways 
being differentially affected by FKBP51, the FKBP5 status appears to at least partially 
influence the re-balancing of those pathways in response to treatment, leading to context 
dependent effectiveness of certain psychopharmaca.  
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5.3 Outlook 
While this work sheds light on the role of FKBP5 in transcription regulation and in 
shaping cellular pathways of psychopharmaca action, it also underlines the 
incompleteness of our current understanding of FKBP5´s action in the therapy of stress 
related diseases. 
With GSK3β, AKT, and ERK, three important kinases with multiple pathway 
connections were observed to be regulated by psychopharmaca. The effects were not 
homogeneous across all psychopharmaca and only loosely followed drug classes. 
Moreover, regulation of these kinases as well as their downstream targets was non-
uniformly influenced by FKBP51. This raises the question of a cell type specificity of 
certain psychopharmaca effects, as different cell types provide differential pathway 
activities. As psychopharmaca presumably take effect in the brain, the analysis of 
pathway regulation by psychopharmaca and the role of FKBP5 in shaping this regulation 
would best be addressed in a mixed culture of the respective neuronal and glial cells. 
Analysis of pathway regulation in a human brain-like context should be approachable by 
the use of induced pluripotent stem-cells (iPSCs). Recently, hippocampal dentate gyrus-
like neurons derived from iPSCs of patients with bipolar disorder were described as a 
human model for stress related diseases (Mertens et al., 2015). With this model, cells 
obtained from patients responding or not responding to a specific psychopharmaca 
treatment could be utilised to characterise pathways relevant for treatment outcome. 
As observed in the FKBP5 knockout cell model, drug regulation of the kinases GSK3β, 
AKT, and ERK as well as their downstream targets was non-uniformly influenced by 
FKBP51. Pharmacologically targeting FKBP51 has recently come into focus, also 
because decreased depression-like behaviour was observed in older mice with deleted 
FKBP5. The original concept was to enhance GR function by inhibiting FKBP51. The 
data presented here underline a role of FKBP51 beyond inhibition of glucocorticoid 
signalling and raise the question of the specificity of FKBP5 targeting drugs. Even an 
FKBP51 ligand specifically disrupting the inhibitory effect of FKBP51 on the 
glucocorticoid receptor would not only affect HPA axis signalling but thereby also lead 
to enhanced transcription of FKBP5 and thus likely enhance functions of FKBP51 
beyond glucocorticoid signalling. Importantly, at least part of these functions have 
already been linked to successful treatment outcome (Gassen et al., 2014, 2015). Indeed, 
it has recently been reported that targeting FKBP51 with a ligand exerted antidepressant-
like effects in mice (Gaali et al., 2015). Hence, it will be interesting to understand how 
this ligand affects pathways beyond glucocorticoid signalling and how this might 
contribute to antidepressant-like effects.  
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